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AML acute myeloid leukemia 
CAR-T-cells chimeric antigen receptors T-cells 
CTL cytotoxic T lymphcytes 
CTLA4 cytotoxic T-Lymphocyte-associated antigen 4 
CyTOF time-of-flight mass cytometry 
DCs dendritic cells 
ECM Extracellular matrix 
EGFR epidermal growth factor receptor 
EMT epithelial-to-mesenchymal transition 
ER estrogen receptor  
ES embryonic stem cells  
FACS fluorescence-activated cell sorting 
FDG fluorescein di-β-galactopyranoside 
FFPE formalin fixed parafin embedded 
FOXP3 forkhead box P3 
GAS6 growth arrest-specific 6 
GFP green fluorescent protein 
GGCX γ-glutamyl carboxylase 
GLA-domain γ-carboxylglutamic acid-rich domain 
HET heterozygous, Axltm1Dgen(LacZ)+/+ 
HMEC human mammary epithelial cell 
IMC Imaging Mass Cytometry 
KO knockout, or Axltm1Dgen(LacZ)+/+ 
  7 
LEP  luminal epithelial progenitor 
LGR5 leucine-rich repeat-containing G-protein coupled receptor 5 
MaSC mammary stem cells 
MEP myoepithelial progenitor 
NSCLC non-small cell lung cancer 
NCS Neighboring channel spillover 
PBS phosphate-buffered saline 
PD1 programmed death receptor 1 
PDL1 programmed death receptor ligand 1 
PtdSer phosphatidylserine 
ROI region of interest 
RTK  receptor tyrosine kinase 
SHGB domain sex hormone-binding globulin 
SMC suspension mass cytometry 
TAM  TYRO3, AXL, MERTK family of RTKs 
TCR T cell receptor 
TEBs terminal end buds 
TM transmembrane domain 
TMA tumor microenvironment 
TNBC triple-negative breast cancer 
tSNE t-distributed stochastic neighbor embedding, specifically the Barnes-
Hut implementation known as BH-SNE 






Axl receptor tyrosine kinase is correlated with epithelial-mesenchymal plasticity, immune 
evasion, metastatic potential and therapeutic resistance. However, its mechanism of action and 
function in normal epithelial cells is unknown. Recent results suggest that Axl is expressed in 
rare mammary and lung epithelial stem cells. In order to study the role of Axl in epithelial 
stem cells we conceived and generated a genetically-engineered Axl lineage-tracing mouse 
model in consultation with an external company.  
 
The primary objective of the study is to elucidate the role of Axl in normal epithelial stem and 
progenitor cells and determine how this function is coopted during malignant transformation. 
To this end, we planned a lineage tracing study with the novel strain that could determine 
whether Axl was a bona fide multipotent stem cell marker in mammary epithelia or induces 
dedifferentiation in committed progenitor cells. In preparation for this study, fluorescence-
based detection approaches for measuring Axl-positive stem cells from the lineage tracing 
strain were evaluated. During these experiments, the strain was extensively genotyped and 
found to not carry the secondary lineage reporter gene due to a strategical error made by said 
company. In addition to standard approaches, an imaging mass cytometry (IMC) panel of 
metal conjugated antibodies was developed for high dimensional spatio-temporal and 
phenotypic tissue analysis. By incorporating many previously reported unipotent and 
multipotent stem cell markers into a single IMC panel, a more definitive stem cell hierarchy 
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1. Introduction 
1.1 Cancer: Prevalence, Origins and Characteristics 
As society continues to advance in terms of both socioeconomic development and global 
health, the incidence and mortality of cancer are rapidly growing worldwide. In countries at 
both ends of the economic spectrum, factors that correlate with reduced prevalence of other 
causes of death, such as increased life expectancy, also correlate with increased cancer 
incidence. Preventative treatment of infectious diseases in third-world countries has resulted 
in a shift towards non-infectious causes of death [1]. In developed countries, increasing levels 
of health awareness combined with advances in treatment and prevention have significantly 
reduced the risk of death from cardiovascular disease; in the United States, cancer is predicted 
to become the leading cause of death within the next five years [2], and has already become 
the leading cause of death in Norway [3]. Globally, cancer is currently the first or second 
leading cause of premature mortality in over half of all countries, and is expected to become 
the overall leading cause of death within the 21st century [4]. Concerning cancer type, the 
most common cancer in females is breast cancer, while lung cancer is the most common cancer 
in males and is responsible for the highest number of cancer-related deaths when both sexes 
are combined (Figure 1.1) [5].
 
Figure 1.1: Age-standardized cancer incidence and mortalities worldwide in 2018 estimated by WHO. Both 
sexes and all ages are included. Data source: Globocan 2018. Graph produced by: Global Cancer Observatory 
(http://gco.iarc.fr/) [5] 
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While the risk factors for other diseases can be mitigated, the primary risk factor for cancer is 
inherently unavoidable; although environmental and lifestyle factors such as smoking, obesity, 
and chronic infections as well as heritable gene mutations can significantly contribute to the 
lifetime risk of some types of cancer, the majority (65%) of variation in the lifetime risk of 
being diagnosed with different cancers can be explained by the number of stem cell divisions 
within the particular tissue in which it arises, which invariably accumulate with age [6]. This 
reflects the widely accepted notion that cancer is caused by the accumulation of genetic and 
epigenetic alterations in cells, the majority of which arise from the endogenous error rate in 
DNA replication during cell division  [7]. The cellular characteristics enabled by these genetic 
alterations can be categorized based on six hallmark capabilities of all cancers proposed by 
Hanahan and Weinberg in 2000: sustaining proliferative signaling, evading growth 
suppressors, activating invasion and metastasis, enabling replicative immortality, inducing 
angiogenesis (blood vessel growth), and resisting cell death [8]. In 2011, two additional 
emerging hallmarks (not yet observed in all cancers): deregulating cellular energetics and 
avoiding immune destruction, and two enabling characteristics (not directly acquired by 
cancer cells but present in cancer-prone tissue environments): tumor-promoting inflammation 
and genome instability, were proposed by the same authors (Figure 1.2B) [9]. Taken together, 
these qualities roughly encapsulate the barriers that cancer cells must overcome to reach 
malignancy. However, the process by which cancer cells acquire and exhibit these traits varies 
both within and between cancer types. As such, cancer should be considered as a heterogenous 
collection of different diseases rather than a single disease.  
1.2 Cancer Development and the Tumor Microenvironment 
Despite the heterogeneity of the underlying molecular mechanisms of tumorigenesis, most 
solid tumors (namely carcinomas, which are cancers derived from epithelial cells) develop in 
a similar fashion, which is depicted in Figure 1.2. 
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Figure 1.2: Stages of tumor development. A single cell gains a mutation that causes it to abnormally 
divide. The cell and its progeny continue to divide faster than the surrounding cells (hyperplasia) until 
one of these cells acquires another mutation that causes it to divide even more rapidly (dysplasia). The 
gain of additional hallmarks from genetic or epigenetic alterations of cells in the dysplasia result in a 
cancer, which is described as in situ so long as it is contained within its tissue of origin. The in situ 
cancer can modulate its surrounding microenvironment and acquire additional mutations in order to 
recruit blood vessels, invade neighboring tissues (becoming malignant), and shed cells into the lymph 
or blood which can establish metastases elsewhere in body. Taken from [10]. 
Human tumors develop over years and decades. As a dormant abnormal cell develops into an 
in situ cancer, the rate of growth increases exponentially between each stage. In addition to 
intracellular changes within the cancer cells themselves, they must also enact changes in the 
surrounding tissue environment, which is normally tumor suppressive in that it maintains 
differentiated cell states and tissue boundaries. Once altered, the complex network of normal 
(non-mutated) cells, extracellular matrix (ECM) proteins, and circulatory and lymphatic 
structures becomes a supportive “niche” referred to as the tumor microenvironment (Figure 
1.3). Cancer cells participate in a bidirectional exchange of signaling factors with the tumor 
microenvironment, coined dynamic reciprocity by M. Bissell, that drives the hallmarks of 
cancer, including angiogenesis (recruitment of blood vessels), sustained growth signaling (by 
secretion of growth factors, hormones and cytokines), invasion and metastasis (through 
degradation of ECM and chemotactic signaling), and immune evasion (by secretion of 
immunosuppressive cytokines), as well as therapy response by modulating the uptake and 






Figure 1.3: The tumor microenvironment. The various constituents include extracellular matrix (ECM), 
stromal cells (cancer-associated fibroblasts, endothelial cells and pericytes) and immune and inflammatory cells 
(T, B, and natural killer ‘NK’ lymphocytes, dendritic cells, macrophages and myeloid-derived suppressor cells). 
Taken from [11]. 
1.3 The evolution of cancer therapy 
The increasing pace of technological development and modern biomedical research has 
spurned a plethora of new cancer therapies, although traditional treatment modalities still 
comprise the backbone of current multimodal treatment regimens for many cancer types. A 
brief chronological overview of these therapies and their relationship to tumor biology is given 
below.  
Surgery 
Up until only a century ago, the only treatment option for cancer was surgery. Typically, these 
surgeries were radical in nature and sought to completely eradicate all traces of tumors to 
prevent relapse. However, tumors were often already too advanced upon diagnosis for surgery 
to be curative. Surgery is a first-line treatment for many cancers and is effective in either 
debulking or completely removing cancerous tissue, particularly when detected at an early 
stage [12].  
Radiotherapy 
Marie and Pierre Curie first discovered that X-ray radiation was harmful to cells and suggested 
its use in the treatment of tumors in 1899 [13]. Ever since, targeted radiation therapy has 
proved to be an effective treatment for shrinking or eradicating solid tumors before, in place 
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of, or after surgery. Toxicity to adjacent normal tissue limits the dose of radiation that can be 
safely administered, and the resulting tissue inflammation elicits both an anti-tumor immune 
response that can be limited by radioresistant suppressor cells and a tumor-promoting wound 
healing response from cells in the tumor microevironment [14].  
Chemotherapy 
The accidental discovery that mustard gas specifically targets rapidly dividing cells in the bone 
marrow after the Second World War beckoned in the era of chemotherapeutics [15]; cytotoxic 
agents that target cancer cells based on their rapid proliferation. These agents cause DNA 
damage (by alkylating agents), inhibition of DNA, RNA or protein synthesis (via 
incorporation of antimetabolites or targeting by antibiotics), inhibition of mitosis (by fungi-
derived antimitotic compounds), or iron deficiency (by iron chelators), and are still widely 
used as first-line treatments for lymphomas, leukemias, and inoperable, advanced or metastatic 
solid tumors [16]. A wide range of chemotherapy combinations have been shown to target a 
broader range of cancer cells at lower doses than single chemotherapeutics while also 
increasing the window in which the treatment is effective before resistance develops. 
Chemotherapy is also particularly useful as a neo-adjuvant or adjuvant therapy (therapy 
administered before or after primary therapy to debulk tumors prior to surgery or reduce the 
risk of recurrence, respectively).  
 
Targeted Therapy 
Significant strides in the field of molecular biology at the end of the 20th century enabled the 
discovery of the soluble signaling molecules and associated downstream intracellular 
signaling pathways responsible for many of the hallmarks of cancer. Synthetic and antibody-
based molecules targeting components of these pathways that are dysregulated in cancer cells 
marked a revolution in cancer therapy. Often cancer cells are “addicted” to these aberrantly 
activated pathways, relying on them for sustained growth and proliferation, and making them 
ideal therapeutic targets. Signal transduction can be upregulated by overexpression of the 
receptor, activating mutations in the receptor or its downstream signaling proteins, or 
inactivating mutations in negative feedback regulators of a given pathway.  
 
In 1970, tamoxifen became the first FDA-approved targeted therapy. Tamoxifen selectively 
binds the estrogen receptor (ER), which prevents it from binding estrogen and acting as a 
proliferation-inducing transcription factor in ER+ breast cancer cells. This paved the way for 
a class of drugs targeting hormone receptors in both breast and prostate cancer [17]. Receptor 
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tyrosine kinases (RTKs) are a large family of transmembrane signaling molecules that are 
activated by dimerization and autophosphorylation upon ligand binding, and regulate many 
important cellular processes including migration, proliferation, dedifferentiation, and survival 
through the recruitment of intracellular signaling cascade proteins to their active sites [18]. 
Although there is significant crosstalk between the signaling pathways activated by these 
receptors, monoclonal antibodies and small-molecule inhibitors targeting specific signaling 
proteins have succeeded in clinical trials for a broad range of cancers, particularly in locally 
advanced or metastatic stages where surgery, chemotherapy, and/or radiation had failed 
(Figure 1.4). Importantly, the clinical efficacy of many of these treatments could only be 
realized when patients were stratified into treatment groups based on molecular testing of their 
cancer status (companion diagnostics), such as fluorescent in-situ hybridization (FISH) to 
select HER2+ breast cancer patients to receive trastuzumab treatment, endothelial growth 
factor receptor (EGFR) mutation assays to select non-small cell lung cancer (NSCLC) patients 
for erlotinib treatment and BRAF-V600E mutation assays to select melanoma patients for 
dabrafenib treatment [17]. For all of the aforementioned drugs, the efficacy of the therapies, 
although initially significant, is eventually thwarted by various resistance mechanisms, some 
of which have yet to be fully understood. In NSCLC, EGFR inhibitor resistance occurs by 
several mechanisms; secondary mutations in the EGFR gene, which has prompted second- and 
third-generation EGFR inhibitors to be developed; activation of alternative survival pathways, 
which has prompted the use of other targeted therapies; and reprogramming of surviving cells 





Figure 1.4: Targeted therapies against 
growth factor signaling cascades in 
cancer. Includes both monoclonal 
antibodies and small molecule 
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Cancer immunotherapy 
In the past decade, the ability of the host immune response to eradicate cancer cells has entered 
the spotlight of cancer therapy. Due the vast number of genetic and epigenetic changes in 
cancer cells that result in the presentation of abnormal protein fragments (neoantigens) on their 
cell surface, they can be recognized and destroyed by host immune cells (anti-tumor 
immunity). In particular, cytotoxic T lymphcytes (CTLs) initiate a lethal granzyme-mediated 
attack on cells when a neoantigen binds its T cell receptor (TCR). However, there are several 
immune checkpoint signaling pathways that mitigate immune destruction of normal tissue 
which are upregulated by cancer cells in order to thwart the recruitment, activation, and attack 
of CTLs. By blocking these inhibitory checkpoint molecules with selective antibodies, anti-
tumor immunity can be unleashed on neoantigen-expressing cancer cells.  
 
The first FDA-approved immune checkpoint inhibitor, ipilimumab, which was approved in 
2010 for advanced melanoma and targets cytotoxic T-Lymphocyte-associated antigen 4 
(CTLA4), an inhibitor of CTL activation. The success of the drug was only acheived when 
administered with multiple doses of a cancer vaccine (melanoma-specifc gp100) that promoted 
an endogenous antitumor immune response particularly in patients whose tumors were not 
inflamed before treatment [19]. Following the success of this treatment, antibodies targeting 
the immune-inhibitory programmed death receptor 1 (PD1) and its ligand (PDL1), which are 
expressed by various immune cells including CTLs and cancer cells, respectively, were 
approved for various indications including melanoma, NSCLC, triple-negative breast cancer 
(TNBC), and gastric, colon, kidney and liver cancers [20]. An alternative approach in which 
T cells are engineered to express artificial chimeric antigen receptors (CARs) that target 
specific tumor neoantigens has also shown considerable success in the treatment of 
hematological cancers [21]. Combined, over 2,000 immuno-oncology agents are currently 
being tested or used in the clinic, including a plethora of combinations between immune 
checkpoint modulators, cancer vaccines, CAR-T cell therapy, targeted therapy, chemotherapy, 
and radiotherapy [21]. A major challenge to the success of these treatments is the identification 
and stratification of patients whose tumors either suppress, exclude, or completely lack 
infiltrating immune cells, and the treatment of these patients with existing or novel therapies 




AXL receptor tyrosine kinase 
In the context of targeted therapy resistance and immuno-oncology, the AXL receptor tyrosine 
kinase (RTK) has emerged as a promising new target to enhance the efficacies of these 
treatments. AXL was initially identified in 1991 as part of the TYRO3, AXL, MERTK (TAM) 
family of RTKs, the last family of RTKs to be discovered [22]. Like many RTKs, the structure 
of the TAM family proteins consists of an extracellular immunoglobulin-1 (Ig1) and Ig2 
binding domain, followed by two fibronectin type III repeats (FN1/2), a transmembrane (TM) 
domain, and an intracellular tyrosine kinase domain (Figure 1.5A). Although AXL activates 
similar downstream signaling pathways as the RTKs in conventional targeted therapy (Figure 
1.4), several properties of AXL differentiate it from other cancer-associated RTKs and its 
TAM family members. First, the two ligands of the TAM family, growth arrest-specific 6 
(GAS6) and protein S (PROS1), contain a γ-carboxylglutamic acid-rich (GLA) domain, and 
EGF and sex hormone-binding globulin (SHGB) domains (Figure 1.5A). The GLA domain, 
when carboxylated by vitamin K-dependent γ-glutamyl carboxylase (GGCX), binds 
phosphatidylserine (PtdSer) in a calcium-dependent manner. PtdSer is a ubiquitous 
phospholipid membrane component which is normally actively sequestered in inner leaflet of 
the plasma membrane but is exposed on apoptotic cells and their resulting vesicles, stressed 
cells, aggregating platelets and signaling exosomes [23]. PROS1 only binds TYRO3 and 
MERTK, while GAS6 has the highest affinity for AXL (mainly at the Ig1 site) and evidence 
suggests that AXL is consituitively bound to GAS6 as a heterodimer in vivo [24]. Thus, 
AXL/GAS6 serves as a unique sensor for PtdSer-presenting membranes, unlike other RTKs 
which respond directly to their ligands, and is robustly activated by receptor clustering when 
PtdSer is localized in high concentrations, namely on apoptotic vesicles (Figure 1.5B). This 
clustering effect has a significant impact on the strength and duration of the signaling input, 
due to the stability of the multimeric PtdSer/GAS6/AXL complex and the spatial exclusion of 
inhibitory phosphatases that otherwise limit the activation of phosphotyrosine signal 
transduction docking sites [25].  
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Figure 1.5: Schematic of TAM receptor/ligand complex (A) and Model of GAS6/AXL clustering and 
activation (B). (A) The TK domains of the TAMR/Gas6 tetramer are strongly activated when GAS6 binds PtdSer 
presented on cell membranes. (B) AXL signaling activation is not correlated with the concentration of its ligand 
GAS6, but is robustly activated when Gas6 is localized to PS-rich membrane surfaces. (A) taken from [26] and 
(B) taken from [24]. 
 
Second, AXL mutations are rarely detected in cancers and it is not considered an oncogenic 
driver, unlike most targeted RTKs. However, its (over)expression in many human cancers is 
associated with poor prognosis, metastasis, and therapy resistance [27]. This can be attributed 
to the cellular characteristics granted by AXL signaling in epithelial cells being more related 
to plasticity (the ability of cells to reversibly alter their phenotype and associated epigenetic 
and proteomic composition) and quiescence (the ability of cells to temporarily enter a non-
replicative, long-lived state), which manifest later in the course of cancer progression and 
treatment relative to the oncogenic signaling aberrations that typically take place during tumor 
development. Additionally, the strength of the signaling stimulus from AXL-GAS6-PtdSer 
clustering, particularly in the context of therapy-induced cell death where large numbers of 
apoptotic bodies are present, means that even ectopic expression of AXL in surviving tumor 
cells is likely sufficient to transform some of them to a resistant and/or invasive state [28].  
Lastly, GAS6/AXL is also employed by a variety of immune cells as a sensor of cell stress 
and apoptotic debris, and consistently acts as an immunosuppressive modulator of antitumor 
immunity; notably, GAS6/AXL has been shown to enhance the suppressive activity of 
regulatory T cells by upregulating forkhead box P3 (FOXP3) and CTLA4 expression [29], 
while AXL was found to be upregulated in cytokine-antagonized dendritic cells (DCs) and act 
an essential negative feedback regulator of toll-like receptor-mediated inflammatory responses 
[30]. Because of its dual function in immunosuppression in the tumor microenvironment and 
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therapy resistance, targeting AXL in combination with chemotherapy, targeted therapy and 
immune checkpoint inhibitors is a novel and promising strategy to increase their efficacy 
(Figure 1.6).  
 
Figure 1.6: Effect of Axl signaling in both the tumor and its microenvironment. Taken from [31]. 
As such, several AXL-targeting therapeutics have emerged and are in various phases of 
clinical development. The most noteworthy of these, the small molecule tyrosine kinase 
inhibitor Bemcentinib, is currently in phase 2 clinical trials for NSCLC (in combination with 
anti-PD1, anti-EGFR, or chemotherapy), TNBC (in combination with anti-PD-1), melanoma 
(in combination with anti-PD1 and chemotherapy), acute myeloid leukemia (AML) and 
pancreatic cancer (in combination with chemotherapy), and recurrent glioblastoma [32-39].  
Although there is a logical explanation for AXL expression in immune cells based on a 
growing body of research, much less is known about the biological function of AXL signaling 
in normal tissues, which is pivotal to understanding how carcinoma cells can coopt these 
mechanisms of plasticity and quiescence to ultimately evade even the most modern cancer 
therapies. 
1.4 AXL and cellular plasticity 
In order to contemplate the role of AXL signaling in normal epithelial tissues, one must 
consider how the characteristics granted by AXL signaling in cancer cells could benefit cells 
during endogenous physiological processes. All of the AXL-related properties illustrated in 
Figure 1.6 are also exhibited by a unique and hotly-debated cell type that is present in various 
forms throughout the body: stem cells.  
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1.1.1. Stem cells in development  
The general consensus on the definition of a stem cell is that it must fulfill two overarching 
properties: the ability to self-renew, and the ability of its progeny to differentiate into one, two 
or multiple restricted lineages or cell types (unipotency, bipotency, or multipotency, 
respectively). The concept of potency is not novel; we have known for centuries that a single, 
totipotent zygote gives rise to the roughly 200 somatic cell types postulated to exist in the body 
[40]. The discovery of receptors, signaling pathways, and transcription factors responsible for 
lineage differentiation and plasticity during embryonic development has been significantly 
aided by mouse models, in which knockouts of individual proteins resulting in developmental 
defects implicated that protein’s essential role in morphogenesis. Strikingly, neither Axl-null 
mice nor any combination of TAM receptor knockouts show any developmental defects and 
only exhibit phenotypes associated with the inability to clear apoptotic cells and reduce 
inflammation and autoimmunity (mediated by Axl and Mertk expression in immune cells), 
decreased blood vessel integrity (mediated by Axl expression in vascular smooth muscle cells), 
and defects in platelet aggregation (mediated by expression of all three TAMRs in platelets) 
[27]. This knowledge constitutes the vast majority of the accepted physiological roles of AXL, 
and many research papers often extrapolate from this limited knowledge directly into the 
prognostic and therapeutic indications of AXL in malignant cells, neglecting that there must 
be a biological purpose for AXL signaling in adult epithelial tissue even though it is typically 
only expressed at low levels [31, 41-43]. 
 
1.1.2. Adult stem cells 
As an organism develops, multipotent cells with an undecided fate differentiate into 
specialized lineages with more restricted fates based on spatiotemporal inputs from 
surrounding cells, growth factors, and ECM components. This can be modeled by 
Waddington’s “epigenetic landscape”, in which the gradual acquisition of epigenetic changes 
guides multipotent cells over the course of many divisions to their specific functions and 
creates an increasingly steep epigenetic barrier between differentiated cells of different 
lineages [44]. However, a small subset of cells in some organs remain fixed at various 
branching points of this hierarchy throughout adulthood, and serve as “hard-wired” stem cells 
that repopulate specialized cell types during normal tissue homeostasis and repair. The 
canonical example is that of hematopoiesis (mature blood cell formation), where progenitor 
cells have been isolated and characterized at nearly every branching point of the differentiation 
hierarchy, from unipotent precursor cells, which divide frequently, to rare multipotent 
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hematopoietic stem cells, which remain in a quiescent state in the bone marrow and divide on 
average only once every two months [45]. Interestingly, AXL is abundantly expressed in both 
physiological and malignant hematopoiesis, providing a rationale for its role in AML 
pathophysiology, therapy resistance and subsequent targeting in combination clinical trials 
[46]. Other diverse examples of well-characterized stem cells include satellite cells, which lie 
dormant for years until recruited to regenerate muscle fibers upon damage, and leucine-rich 
repeat-containing G-protein coupled receptor 5 (LGR5)-expressing intestinal crypt cells, 
which divide frequently (up to 1,000 divisions per lifetime) to feed the rapid tissue turnover 
rate of intestinal epithelium [45]. In this case, however, it was shown that quiescent, 
differentiated +4 crypt cells can dedifferentiate when LGR5+ stem cells are ablated, regaining 
the LGR5+ multipotent phenotype [47]. This raises the notion that differentiation is not 
necessarily unidirectional; in conditions such as organ regeneration and remodeling where 
resident stem cells cannot meet the demands of repopulation, lineage-restricted cells can be 
reprogrammed to act as facultative stem cells [48]. This reprogramming potential is referred 
to as cellular plasticity. 
 
1.1.3. Plasticity versus committed progenitors 
Two pivotal examples of plasticity-induced dedifferentiation superseding and/or contradicting 
the established hierarchy of committed stem/progenitor cells can be found in the mammary 
and lung epithelia. The mammary gland is comprised of two distinct epithelial lineages: 
luminal and basal. Luminal cells line the interior of the mammary ducts and differentiate into 
ductal and alveolar cells during pregnancy to secrete water and nutrients, respectively, in the 
form of milk, while basal cells are highly-elongated and in direct contact with the basement 
membrane, forming an outer myoepithelial layer around the luminal cells that contracts in 
order to stimulate secretion and milk flow throughout the ductal tree [49, 50]. During puberty, 
mammary ducts undergo a massive hormone-induced expansion, where branching terminal 
end buds (TEBs) penetrate into the underlying mammary mesenchyme (fat pad). Two 
opposing hypotheses exist concerning the nature of mammary stem cells (MaSCs) and their 
role in mammary gland remodeling and homeostasis based on evidence from classical mouse 
model experiments. On one hand, a lineage tracing study independently tracking unipotent 
basal and luminal progenitors and their progeny in vivo demonstrated that each lineage is 
maintained independently throughout puberty and pregnancy (Figure 1.7A) [50]. On the other 
hand, ex vivo transplantation of putative bipotent basal MaSCs into cleared mammary fat pads 
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has demonstrated that they can reconstitute the entire dual-lineage structure of the mammary 
gland (Figure 1.7B). Crucially, our group has shown that Axl serves as a putative bipotent 
MaSC stem/progenitor marker in mice using the same experimental strategy (Figure 1.7C) 
[51]. 
Figure 1.7: Conflicting experiments regarding the nature of mammary stem cells in homeostasis and 
remodeling. (A) Lineage tracing of unipotent myoepithelial (basal) and luminal progenitors through puberty and 
lactation suggests they independently maintain their respective lineages. Fluorescence-activated cell sorting 
(FACS) of putative myoepithelial mammary stem cells based on surrogate marker expression (B) or AXL 
expression (C) demonstrates their multipotency through their ability to reconstitute the entire mammary gland 
structure in cleared mammary mesenchyme. FDG: fluorescein di-β-galactopyranoside, a reporter molecule for 
Axl+ cells in Axl/LacZ heterozygous mice. A and B adapted from [52] and C taken from [51]. 
 
One critique of the ex vivo reconstitution assay is that it removes cells from their in situ niche, 
which may apply novel environmental pressures not normally encountered in vivo that induce 
dedifferentiation. However, our group has also shown that AXL+ myoepithelial cells are 
poised at the apex of the human mammary epithelial cell (HMEC) hierarchy in vivo based on 
flow cytometric analysis of isolated primary HMECs stained with markers for AXL and 
various lineage-specific cell surface receptors (Figure 1.8A) [51]. Additionally, a functional 
Axl-knockout mouse model generated by our group showed significantly reduced ductal 
branching and morphogenesis and a pro-luminal phenotype compared to wild-type mice [51]. 
Paradoxically, another group recently reported that Gas6-knockout mice showed no 
impairment of ductal morphogenesis [53]. Returning to Waddington’s epigenetic landscape, 
it is unclear whether AXL+ multipotent cells permanently reside in a specialized niche, arise 
from dedifferentiation of AXL+ basal cells, or some combination of the two (Figure 1.8B), 
while the role of AXL signaling in mammary gland remodeling and homeostasis has yet to be 
determined.  
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Figure 1.8: AXL in the mammary stem cell hierarchy. (A) Spanning-tree progression analysis of density-
normalized events (SPADE)-generated hierarchical trees from multicolor flow cytometry data of primary 
HMECs isolated from patient reduction mammoplasty tissue samples and stained with 
CD326/CD49f/CD227/CD10/Axl markers. Each circle represents a distinct cell subpopulation that is most 
related to its nearest neighbors and whose size is proportional to the relative number of cells. Relative expression 
of CD227, a luminal epithelial (LEP) marker, CD49f, a myoepithelial (MEP) marker, or Axl in each 
subpopulation is shown on a blue to red (low to high expression) scale. Differentiated LEP and MEP cell 
populations comprise the left and right lineage branches, respectively, while Axl is expressed primarily in the 
putative bipotent MaSC populations found at the apex of the hierarchical tree. (B) Two possible scenarios for 
Axl expression in bipotent MaSCs imposed on Waddington’s epigenetic landscape. Axl+ cells are either 
maintained in a niche at the apex of the hierarchy (yellow), arise from dedifferentiation of committed Axl+ 
myoepithelial cells (red), or some combination of the two. Φ corresponds to the level of epigenetic differentiation 
and lineage commitment from a multipotent state, while Ψ corresponds to deterministic splits between two cell 
fates in the hierarchy, and also correlates strikingly well with the branching points in (A). A taken from [51] and 
B adapted from [44].  
 
In the mammalian lung, cellular plasticity has been observed in both the airway and alveolar 
epithelia during non-homeostatic conditions. Mucus-producing club cells in the airway ducts 
serve as bipotent progenitors of their own lineage and that of ciliated cells, which move mucus 
and particles out of the lung. Quiescent, multipotent basal cells can give rise to all airway 
lineages in response to tissue damage, but when these cells were experimentally ablated, it 
was shown that fully mature club cells could actually dedifferentiate into basal stem cells [54]. 
Similarly, among the two cell types of the alveolar epithelium, type 2 cells, which steadily 
secrete surfactant to prevent alveolar collapse, were shown under homeostatic conditions to 
generate both type 2 and type 1 cells, which participate in gas-exchange and form the thin 
lining of the alveolar sacs. During injury-induced lung regeneration, type 1 cells have also 
been inversely shown to generate bipotent type 2 stem cells [55]. Although AXL has not been 
explicitly implicated in either of these dedifferentiation processes thus far, its role in plasticity-
induced resistance to anti-EGFR therapy in NSCLC has been clearly demonstrated by our 
group and others [28, 56], and suggests that AXL may play a role in normal lung epithelial 
plasticity.  
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1.5 Current Research Focus 
AXL RTK serves as a unique sensor of apoptosis and cell stress and its signaling pathways 
are clearly employed by both tumor and associated immune cells to thwart various cancer 
therapies. While the clinical data from targeting AXL in cancer appears promising, it is also 
important to understand the role of AXL-induced cellular plasticity in normal epithelia by 
finding and characterizing rare AXL+ cells during normal homeostasis as well as organ 
remodeling and repair. In our group in particular, in accordance with the clinical trials of 
bemcentinib in TNBC and NSCLC, we seek to build on our existing evidence that AXL is a 
bona fide MaSC marker and explore the possibility that this is also the case in lung epithelia.  
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2. Methodological Considerations 
In this section, the unique methods employed in the scope of this work are discussed in detail. 
All standard techniques as well as the detailed protocols of the applications mentioned below 
can be found in Section 3.  
2.1 Mouse Models 
Animals can serve as useful model systems to study disease pathology as well as normal 
physiological processes. Mice are ideal for these studies because they provide an optimal 
balance between genetic/physiological similarity to humans and ease of maintenance due to 
their small size and rapid maturation rate. Various disease models in animals use standardized 
approaches to induce disease via exposure to pathological agents or genetic manipulation. 
Recent advances in the fields of genetics and genetic engineering have enabled many elegant 
transgenic systems that can target specific genes in mice. Two such systems utilized in the 
current work are described below.  
2.1.1 Gene targeting by homologous recombination 
Insertion or deletion of genetic material can be achieved by homologous recombination in 
mouse embryonic stem (ES) cells, producing transgenic mice. Homologous recombination is 
a naturally occurring process that is observed most frequently in meiosis of gamete cells, and 
is responsible for the randomization of inherited alleles. Human somatic cells contain two 
distinct copies of their genome per cell (2N), one from each parent. Variations at specific 
points along the genome are referred to as alleles, and when taken together, comprise the 
genetic diversity of a given species. When gamete cells divide, chromosome pairs from each 
parental genome overlap randomly at various matching points, where conserved homologous 
sequences align with each other and recruit enzymes that break, swap and recombine the ends 
of the chromosome pairs. When the gamete cells divide again in meiosis, the resulting 
daughter cells contain a unique 1N genome that does not match that of either parent due to 
various homologous recombination events. This process also occurs sporadically in normal 
cells, which can sometimes result in aberrant activation of oncogenic signaling pathways 
through the generation of fused proteins. By exogenously introducing high concentrations of 
linearized, double-stranded synthetic DNA constructs containing sequences homologous to 
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the specific genetic locus of interest, homogenous recombination can be induced in mouse ES 
cells [57]. Insertion or “knock-in” of genetic material (flanked by homologous sequences) 
through this process is generally more efficient than deletion, and enables a diverse arsenal of 
transgenic expression systems when executed correctly.   
2.1.2 Axl-LacZ knock-in model 
The Axl gene consists of 20 exons (protein coding regions), which sequentially code for each 
domain of the receptor starting at the extracellular ligand binding domain. Inserting the LacZ 
gene, which encodes bacterial β-galactosidase (β-gal), into exon 11 of the mouse Axl gene 
using homologous recombination interrupts normal expression of Axl, serving as a functional 
knockout in homozygous B6.129P2-AXLtm1Dgen/Jmice, hereafter referred to as Axl-LacZ 
mice (Axl-LacZ-KO, Figure 1.9). It also produces functional β-gal under control of the Axl 
promoter, which can be used to detect Axl+ cells in heterozygous Axl-LacZ/Wt mice (Axl-
LacZ-HET) since they still have a functional copy of Axl in the wild-type allele. β-gal+ cells 
are detected by addition of β-gal substrates; the X-gal enzymatic product can be detected 
colorimetrically in tissue sections, while addition of fluorescein di-β-galactopyranoside (FDG) 
produces a fluorescent product measurable by flow cytometry. As mentioned in the 
introduction, Axl knockout mice are viable but have been shown by our group to exhibit 
reduced cellular plasticity and remodeling in the mammary gland, however a deeper 
interrogation of this and other epithelial tissue is required to solidify Axl’s role in these 
processes.  
 
Figure 1.9: Description of the AXL-targeting mutation in B6.129P2-AXLtm1Dgen/Jmice. Schematic 
illustration of theLacZ-Neocassette insertion site in exon 11 of the murine AXL gene, disrupting AXL protein 
expression. A 5’ splice acceptor ensures that the LacZ open reading frame is spliced into the endogenous AXL 
mRNA under control of the murine AXL promoter. 
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2.1.3 Axl-Cre lineage tracing model  
The ability to permanently mark cells expressing a given marker at a specific timepoint such 
that their progeny can be detected independently of the original marker expression in situ is 
known as lineage tracing. Although this technique has proven useful in identifying 
professional, hard-wired stem cells in other organs (Section 1.4.2), numerous lineage tracing 
mouse models targeting putative MaSC markers have failed to identify a multipotent 
progenitor population [58]. However, considering our existing evidence from normal 
mammary epithelia and the propensity of Axl to regulate plasticity in breast carcinomas, we 
believe that an Axl lineage tracing model could significantly advance our understanding of 
MaSC plasticity.  
 
The most common inducible lineage tracing approach involves co-expression of an exogenous 
DNA recombinase with the marker of interest. This recombinase, when expressed as a fusion 
protein with the binding domain of a hormone receptor, is sequestered in the cytoplasm and 
can only enter the nucleus when the receptor moiety binds an exogenously administered 
hormone. Once inside the nucleus, the recombinase binds specific sites and excises a stop 
codon sequence from a transgenic reporter gene located near a ubiquitously expressed 
promoter region. (A wide variety of transgenic reporter strains possessing different 
recombinase-activated or silenced fluorescent reporter proteins are commercially available 
that can be crossed with the customized lineage-tracing strain.) The stop codon is permanently 
excised in all cells expressing the marker of interest at the time of hormone administration, 
meaning that those cells and their progeny will continue to express the reporter protein as long 
as their lineage persists. A diagram depicting the Axl-Cre lineage tracing system proposed in 
this study is shown in Figure 2.1. 
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Figure 2.1: Axl-CreERT2-GFP/Rosa26-CAG-tdTomato lineage tracing system. A specialized knock-in strain 
coexpressing Axl, CreERT2 fusion protein, and GFP under control of the Axl promoter (A) is crossed with a 
reporter strain containing the tdTomato fluorescent protein coding sequence preceded by a loxP-flanked stop 
codon under control of the ubiquitously-expressed CAG protomer at the Rosa26 locus (B) to produce mice that 
are homozygous for both transgenic alleles. When these mice are administered tamoxifen (C), it binds the ERT2 
receptor domain, allowing the CreERT2 fusion protein to enter the nucleus and excise the stop codon, irreversibly 
activating tdTomato reporter expression (D). loxP: exogenous recognition sequence for Cre recombinase.  
 
As an added feature, GFP is coexpressed with Axl in this system, allowing us to differentiate 
Axl-GFP-tdTomato+ cells from their tdTomato+ progeny. However, the expression of three 
separate proteins from a single promoter requires dedicated genetic engineering using 
expression elements from viral systems. A schematic of the Axl-CreERT2-GFP knock-in 
construct is shown in Figure 2.2, and the purpose of each component in the construct is 
summarized in Table 2.1.  
 
Figure 2.2: (A) Mouse Axl wild-type (Wt) gene. (B) Axl-CreERT2-EGFP knock-in (KI) construct. The homologous 
recombination vector sequence is indicated by the orange box, while the entire length of the segment represents the Axl gene 
targeted locus after recombination. The arrow indicates the insertion site of the vector on the Axl gene. Blue boxes: exons of 
the Axl receptor gene; IRES: Internal Ribosome Entry Sequence; cre: Cre recombinase protein coding region; eGFP: 
enhanced Green Fluorescent Protein coding region; ERT2: Estrogen Receptor Transferase 2 protein coding region; neo: 
neomycin selection cassette; FRT: Flp Recombinase Target sequence; UTR: untranslated region (of Axl gene). 
 




IRES Forms secondary mRNA structure that allows ribosome binding and 
5’cap-independent expression of additional proteins from a single mRNA 
[59] 
eGFP Fluorescent protein coexpressed with Axl to distinguish Axl+ cells 
P2A Self-cleaving peptide sequence that allows synthesis of multiple proteins 
from a single open reading frame [60] 
ATG Start codon (methionine), helps continue translation past P2A sequence 
Cre Recombinase that excises stop codon from transgenic reporter gene locus 
ERT2 Domain of estrogen receptor, restricts translocation of fusion proteins to 
nucleus until binding tamoxifen 
FRT Flp recombinase recognition sequence for excision of neo cassette 





The question of whether Axl+ cells in the mammary epithelium are true MaSCs that 
differentiate into the unipotent basal and luminal progenitors postulated to maintain their 
respective lineages throughout adulthood, or are facultative stem-like progenitor cells that 
dedifferentiate to assist in organ remodeling can be addressed by administering tamoxifen to 
female Axl lineage tracing mice both before and at the start of puberty (Figure 2.3). 
Figure 2.3: Proposed Axl lineage tracing study in mammary development. Two groups of mice are 
administered tamoxifen to induce tdTomato (RFP) expression of Axl+ MaSC and their progeny at different 
timepoints relative to the start of puberty. Mammary glands are harvested from sacrificed mice at different 
timepoints in development and interrogated by multiple complimentary analytical methods. IF, 
immunofluorescence; IMC, imaging mass cytometry; FACS, fluorescence-activated cell sorting. Mammary 
development illustration taken from [61]. 
If Axl+ cells are indeed the precursors of unipotent luminal and basal progenitors and sit at 
the apex of the mammary stem cell hierarchy, then more tdTomato-expressing cells should be 
visible in group 1 than in group 2. If Axl+ cells are quiescent and are only recruited as 
multipotent progenitors during organ remodeling, then the number of tdTomato-expressing 
cells should be roughly equivalent between the groups. Although standard fluorescence 
imaging techniques provide the core conclusions from the study, much more insight can be 
gained by examining these mammary glands using organoid assays and highly multiplexed 
image analysis, which are described below.  
2.1.4 Organoid assays 
When studying a subpopulation of cells based on their marker expression in situ, clonal 
heterogeneity can cause these seemingly similar cells to exhibit different traits. In order to 
examine the behavior of single cells in vitro, they can be isolated from tissues, seeded into an 
ECM-rich gelatin and grown into 3D organoids. This technique provides a succinct advantage 
over 2D cell culture techniques by allowing cells to coordinate their growth and differentiation 
in 3D space, which more accurately reflects the in vivo environment. Organoids also serve an 
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ethical purpose by displacing the use of animal models, and are much easier to upscale, 
monitor, analyze, and treat directly with various biological agents. They often are employed 
as a powerful complimentary approach in lineage tracing studies, where putative stem cells 
and their progeny can be isolated and sorted into organoid cultures to observe lineage 
heterogeneity and multipotency in vitro. 
2.2 Imaging mass cytometry 
Imaging mass cytometry (IMC) is a novel technique that enables highly multiplexed imaging 
of tissue sections by staining them with heavy metal-conjugated antibodies. It was first 
conceived by Bodenmiller et al. as a complimentary method to suspension mass cytometry 
(SMC) a.k.a. time-of-flight mass cytometry (CyTOF) [62], which has already gained 
significant popularity (particularly in the field of immunology) upon the launch of 
commercially available mass cytometers from Fluidigm starting in 2009 (originally DVS 
Sciences, acquired by Fluidigm). While standard immunofluorescence imaging methods can 
detect a maximum of 5-7 different fluorophore-conjugated antibodies due to overlap of 
emission spectra, the resolution of mass cytometry currently enables the detection of over 40 
heavy metal-conjugated antibodies simultaneously with minimal signal spillover. The 
platform has the potential to be expanded to up to 100 markers as more isotopes of rare earth 
metals continue to be isolated and made available for antibody conjugation [62].  
2.2.1 Applications in stem cell and cancer research 
Observing stem cell plasticity in various states of differentiation or dedifferentiation is an 
enormous challenge; the use of a single lineage-specific marker per cell type plus one or two 
candidate stem cell markers and a nuclear stain already pushes the upper limits of standard 
fluorescence imaging approaches, and is usually insufficient to identify subpopulations of cells 
within lineages or in a transient state. By incorporating many lineage-specific and previously 
proposed uni/multipotent progenitor markers as well as the reporter proteins from our lineage 
tracing model into tissue-specific IMC panels, single cells can be much more accurately 
mapped to the epigenetic landscape in relation to our proposed model of AXL-induced stem 
cell plasticity, all within the spatial context of a single tissue section. Furthermore, the addition 
of signaling markers in the form of phosphotyrosine antibodies can eludicate the intracellular 
mechanisms of Axl signaling in different contexts. Finally, the ability to simultaneously stain 
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ECM components and other cell types including immune cells and fibroblasts may reveal 
novel interactions indicative of a supportive stem cell niche. 
All of these metrics are also valuable in the context of the tumor microenvironment, where 
similar processes are thought to occur as cancer stem cells remodel the surrounding cells and 
tissue into a supportive niche [63]. In this case, marker emphasis should be shifted from 
subtyping of epithelial lineages (which are already highly dysregulated in tumors) to subtyping 
of immune cells and their degree of infiltration, which plays a major role in prognostic 
outcome and sensitivity to modern therapies.  
2.2.2 Sample workflow and technological overiew 
The workflow for a typical IMC experiment is shown in Figure 2.4. 
 
Figure 2.4: Workflow of a typical IMC experiment. At the time of publication of this figure in 2014 (taken 
from [62]), only 32 metals were available for antibody conjugation, but now up to 40 metals are available.  
In a typical IMC experiment, a solid tissue sample (either frozen or FFPE) is sectioned 
(standard thickness of 5 µm), mounted on glass slides, deparaffinized and rehydrated (FFPE 
only), subjected to antigen retrieval conditions to expose masked/crosslinked antigens, 
blocked with serum proteins to reduce nonspecific binding, and stained with a cocktail of 
metal-conjugated antibodies followed by a heavy metal DNA intercalator. Regions of interest 
(ROIs) on stained sections are ablated and analyzed by the IMC instrument, which measures 
the heavy metal content in each ablated segment of tissue (approximately 1 µm2) and 
corresponds to individual pixel intensities in the greyscale output images for each 
metal/marker channel. These multiplexed images are then subjected to cell segmentation using 
DNA staining images to identify nuclei and structural marker images to identify cytoplasm 
and cell boundaries (when applicable), and exported with an accompanying cell segmentation 
mask to various data analysis pipelines (described in section 2.2.5). 
  31 
As of August 2019, there is only one commercially available IMC instrument, the Hyperion 
Imaging System, which is sold by Fluidigm and couples with either of their two most recent 
CyTOF systems (CyTOF2 and Helios). A schematic of the Hyperion system coupled to the 
Helios along with a detailed explanation of its function is shown in Figure 2.4. 
 
Figure 2.4: Schematic of the inner workings of the Hyperion and Helios. A sample slide with a mounted 
section stained with a cocktail of metal-tagged antibodies is loaded in the ablation chamber (purple) of the 
Hyperion system. An LED-based optical imaging system acquires a panorama of the sample and can also monitor 
sample ablation by an attenuator-pulsed laser focused through the same objective lens (yellow) that rasters along 
the tissue. Each laser pulse that strikes the sample produces a plume of ablated material, which is collected into 
a coupling tube and transferred to the Helios using an inert Argon carrier gas. The the ablated sample material in 
the plume is vaporized, atomized, and ionized in the inductively coupled plasma (ICP) torch (pink). Uncharged 
atoms and low mass elemental ions are consecutively filtered out with a deflector and high pass optical filter, 
respecitvely (grey), and the resulting ion plume is accelerated in discrete slices into the time-of-flight (TOF) 
chamber (blue), where ions are separated by their mass (momentum) according to the time it takes them to reverse 
direction in an electromagnetic field. The mass-separated ions hit a detector which produces an analog signal that 
is amplified, digitized, and converted to individual counts of each heavy metal isotope in the plume slice (black). 
The counts are summed from all slices in the plume to yield a pixel intensity for each metal, which are assembled 
into the final output images. Schematic taken from the Hyperion Imaging System user guide (Fluidigm PN 
400311 A2).  
2.2.3 Antibody conjugation 
In order for antibodies to be used to detect various proteins in IMC, they must be conjugated 
with heavy metals. The most commonly used strategy (although others exist) is to partially 
reduce the disulfide bridges between the heavy and light chains, breaking some of the bonds 
and reducing them to thiol groups. A chelating polymer containing maleamide groups that 
readily react with the thiols is pre-loaded with lanthanide (heavy metal) ions, and when 
combined with the partially-reduced antibody, catalyzes a covalent bond permanently linking 
the heavy metal to the antibody though a maleamide-sulfide bridge (Figure 2.5). The polymer 
and residual metals are washed away via spin column purification. Both the metal conjugation 
and the antibody recovery from the spin column have varying efficiencies, and partial 
reduction of some antibodies can eliminate their antigen binding capabilities; therefore, 
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antibodies must ideally be tested for metal content (by running through a the CyTOF at a 
diluted concentration) and binding specificity by IMC or  before using in regular experiments. 
 
Figure 2.5 Conjugation chemistry of the MaxPar polymer-mediated antibody conjugation process. Taken 
from the MaxPar Antibody Labeling Kit protocol (Fluidigm, PRD002 Version 11) 
2.2.4 Panel Development Strategy 
Many considerations must be factored into the design and development of an IMC panel; 
foremost is the selection of markers and corresponding targeting antibodies to test and include, 
as well as which heavy metal channel a particular marker should be detected in if there are 
conjugates (pre-conjugated antibodies) available in multiple channels or if the antibody must 
be conjugated in-house. Priority is given to markers central to the research goals being 
addressed, which in this case is Axl/GFP and tdTomato (RFP), followed by markers that can 
assign an approximate phenotype to every cell type expected to exist in the given tissue (LEP, 
MEP, fibroblasts, and immune cells in the mammary), then pan-structural markers for the 
identification of cytoplasm for cell segmentation and ECM components to denote tissue 
compartments and cell-ECM interactions, and finally other research markers of interest that 
can further segregate various cell types (including epithelial lineages and immune cells) into 
smaller subpopulations or elucidate signaling mechanisms. For markers with relatively low 
abundance in the tissue of interest, it is recommended by Fluidigm to use metals within the 
153-176 Da range, where the instrument is most sensitive (Fluidigm Panel Design Guidelines, 
PN 13-01_150711). In our group, a large inventory of existing conjugates were already 
available from our ongoing CyTOF experiments, which provided the advantage of not having 
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to build a panel completely from scratch. The general strategy employed in this study for the 
testing and inclusion of antibodies into epithelial stem cell-oriented panels for mammary and 
lung tissue is shown in Figure 2.6.  
 
Figure 2.6: Antibody conjugation strategy for this study. The majority of the experiments focused on the first 
two steps, where a large inventory of existing suspension mass cytometry antibodies were tested in IMC and 
more Hyperion-validated antibodies were acquired and added to a backbone of pre-tested antibodies from the 
first step. Finally, tissue specific markers were conjugated and incorporated into the panel. If unique detection 
modalites are desired, some channels can be devoted to other techniques that expand on the platform, such as 






3. Project Aims 
Overall Aim: Elucidate the role of Axl in normal stem epithelial cells and determine how this 
function is coopted during malignant transformation. 
 
Central Hypothesis: Axl signaling induces cellular plasticity in normal epithelia in response 
to non-homeostatic conditions, specifically in those of the mammary gland ducts during 
puberty and lung alveoli during regeneration and repair, which provides an evolutionary and 
mechanistic link to Axl signaling in cancer. 
 
Specific Aims: 
1) Breed and characterize Axl-CreERT2-GFP and Axl-CreERT2-GFP/Rosa26-tdTomato 
mouse strains to study the functional properties of Axl+ stem cells in vivo and in vitro  
This aim focuses on the genotyping and selective breeding of mice generated by Ozgene in 
order to establish homozygous transgenic strains for use in in vivo lineage tracing studies and 
in vitro functional studies using cell culture and organoids. Standard fluorescence-based 
imaging and flow-cytometry approaches are performed using the Axl-CreERT2-GFP strain for 
eventual application in a Axl-CreERT2-GFP/Rosa26-tdTomato mammary stem cell lineage 
tracing study. 
 
2) Develop an IMC panel for interrogation of stem cell dynamics in breast and lung tissue 
and in vitro organoid sections  
This aim endeavours to establish an IMC panel of up to 40 metal-conjugated antibodies to 
allow measurement of stem cell dynamics in situ in various epithelial tissues and their derived 
organoids at a high spatiotemporal resolution. The IMC panel is designed and iteratively tested 
on the Hyperion imaging system using an existing CyTOF antibody inventory and new 
antibodies conjugated commercially or in-house.  
 
3) Establish an IMC analysis pipeline and repository of antibody testing data to enable 
the use of the platform to study Axl+ stem cells 
This objective of this aim is to synthesize all of the troubleshooting issues, antibody feasibility 
testing and data analysis pipeline optimizations addressed in the current work into actionable 
recommendations and strategies that empower other users and future experiments. 
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4. Materials and Methods 
4.1 Mouse Models 
The generation, breeding, and experimental use of all mice listed in this paper was approved 
by the Norwegian Food Safety Authority and performed in accordance with the Regulation on 
Animal Experimentation (Norecopa). The background of all mice was C57BL/6J. 
4.1.1 Generation of Axl-CreERT2-EGFP knock-in mice 
This work was performed by a commercial vendor (Ozgene Inc., Perth, Australia) in 
consultation with our group. Embryonic stem (ES) cells isolated from C57BL/6J mice were 
transfected with the linearized gene targeting vector previously illustrated in Figure 2.2. Upon 
transfection, the gene targeting vector is sporadically incorporated into the target locus during 
cell division by homologous recombination due to its sequence overlap with exon 20 of the 
Axl gene on its flanking ends. The small fraction of resulting transgenic ES cells were then 
selected from wild type cells by exposure to neomycin, as they express a resistance cassette, 
and injected into proprietary goGermLine blastocysts. The resulting male offspring produced 
only ES cell-derived transgenic offspring that were heterozygous for the Axl knock-in allele, 
which were subsequently crossed with homozygous Rosa26-Flp mice. The ubiquitously 
expressed flp recombinase excises the FRT-flanked neomycin resistance cassette from the 
knock-in construct in the resulting offspring, since it can have unintended effects on the target 
gene or surrounding genes [64]. A final round of breeding was performed to select for 
homozygous Axl-CreERT2-EGFP mice (all heterozygous Rosa26-Flp/Wt) which were 
shipped to our animal facility. In addition, some of these mice were crossed with homozygous 
Rosa26-TdTomato mice (Jackson labs, stock number 007905) and the offspring were inbred. 
From this litter, homozygous Axl-CreERT2-EGFP mice that were heterozygous for Rosa26-
TdTomato were selected and shipped to our animal facility. All mice were selected using a 





4.1.2 Genotyping and breeding of mice received from Ozgene 
Once the mice arrived from Ozgene, two breeding objectives needed to be completed before 
any experiments could take place: (1) Cross the homozygous Axl-CreERT2-EGFP Rosa26-
Flp/Wt mice to selectively breed out the Flp allele and establish a long-term stock colony that 
could be bred to other Cre-based reporter strains in future experiments, and (2) cross the 
homozygous Axl-CreERT2-EGFP Rosa26-TdTomato/Wt mice to selectively breed out the Wt 
allele so that these mice could be used in lineage tracing experiments. When establishing a 
transgenic strain, it is ideal to select and maintain mice that are homozygous for each 
transgenic allele so long as heterozygotes are not required for experiments since homozygous 
mice can be bred with impunity and require less genotyping surveillance. Additionally, having 
two copies of each reporter gene in the lineage tracing mice maximizes their expression and 
subsequent fluorescent signal in experiments, which is particularly relevant considering the 
rarity of Axl-expressing stem cells in the tissues being interrogated. Consistent with our 
concurrent genotyping of other strains, endpoint PCR was used to genotype the Axl-CreERT2-
EGFP mice, and all primers used are shown in Table 4.2. 
Table 4.2 Primer sequences used to genotype Axl-CreERT2-EGFP mice 
 
Genotyping assay optimization 
Since the original mice from Ozgene had already been genotyped at their facility before being 
sent to us, DNA samples taken from these mice served as positive controls for our genotyping 
assays. DNA was extracted from mouse ear punches as follows: 2mm ear punch biopsies were 
added to 75µl of a solution containing 25mM NaOH and 0.2mM EDTA, pH ~12 and incubated 
for 95°C for 30 minutes, cooled to 4°C, then quenched with 75µl of 40mM Tris-HCl, pH ~5. 
This crude lysate was used as DNA template for the subsequent PCR assays. A list of all 
reagents and all thermal cycle conditions used in the genotyping assay optimization can be 
Target allele Forward (F) and Reverse (R) primer sequences (5’-3’) Product length Source 
Axl-CreERT2-
EGFP knock-in 
F: CATGGACTGCATCTGAGAAGGG  
R: CCTAAGGATTCCTGTAGCTGTCTC 




Axl-Wt F: CATGGACTGCATCTGAGAAGGG 
R: ATGGAGCATCTGTACAGCATGAAG 
286 base pairs 
Rosa26-Flp F: TAGAACAGCTAAAGGGTAGTGC 
R: TTACACCTGTTCAATTCCCCTG 
538 base pairs Ozgene stock 
genotyping assay 
Rosa26-Wt F: AAGGGAGCTGCAGTGGAGTA 
R: CCGAAAATCTGTGGGAAGTC 













  87 base pairs Ozgene RT-PCR 
assay 
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found in Tables 4.3 and 4.4, respectively. All runs in our lab were performed on an Eppendorf 
950000015 Mastercycler Gradient thermal cycler and analyzed on 1% (w/v) agarose gels. 
Reagent Supplier Product Number 
KlearKall (enzyme/mastermix, 2X) Biosearch 
Technologies 
KBS-1001-001 
Phusion HF polymerase kit (+5X HF buffer, MgCl2)  Thermo Fisher F530S 
Q5 High-Fidelity DNA polymerase NEB M0491S 
Q5 High-Fidelity 2X Master Mix NEB M0492S 
dNTP solution mix NEB N0447S 
Betaine Merck B2629 
AmpliTaq Gold DNA Polymerase with Gold Buffer Applied 
Biosystems 
4311806 
Primers, lyophilized (see table 3.2) Merck Custom order 
O’GeneRuler 1kb DNA ladder and 6X loading dye Thermo Fisher SM1163 
Table 4.3 Reagents used in PCR genotyping assay optimization. 
 
 
Table 4.4: Thermal cycle conditions used in PCR genotyping assay optimization. All 
temperatures are in degrees Celsius. Gradient represents a range of annealing temperatures across 8 wells. The 
Jackson protocol uses a “touchdown” strategy where the annealing temperature starts at 65°C and decreases by 
0.5°C per cycle until it reaches 60°C for the rest of the cycles. 
 
Once the genotyping assays had been optimized to detect the Rosa26-Flp/Wt and Axl-
CreERT2-/Wt alleles, they were used to selectively breed out the Flp allele and establish the 
Axl-CreERT2-EGFP stock strain. This strain was then used in Axl-GFP characterization 
experiments.  
4.1.3 Characterization of Axl-GFP expression in Axl-CreERT2-EGFP mice 
In order to evaluate experimental methods crucial to the Axl-CreERT2-EGFP/Rosa26-
TdTomato lineage tracing study and observe the distribution of Axl-GFP expression in various 
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organs, two approaches were pursued: (1) observe spatial distribution of Axl-GFP+ cells via 
fluorescence imaging of tissue cryosections and whole-mounted mammary glands, and (2) 
determine the frequency of Axl-GFP+ cells in lung and mammary gland by dissociating the 
tissue and measuring cells via flow cytometry. 
 
Axl-CreERT2-EGFP 12-week-old female mice were placed in an isoflurane chamber until 
unconscious, sacrificed via neck dislocation, and transcardially perfused with ~5 mL 
phosphate-buffered saline (PBS). Various organs, including lung, kidney, spleen, and 
mammary glands, were dissected and harvested. One inguinal mammary gland was whole 
mounted to SuperFrost Plus microscope slides (Thermo) while the other glands were placed 
in a petri dish for dissociation. One lung was also placed in a petri dish for dissociation, while 
the other was submerged in Tissue-Tek OCT compound (VWR) and flash-frozen in liquid 
nitrogen along with the rest of the harvested organs. For the remainder of all experiments 
using these organs, samples were protected from light to preserve fluorescent protein signal.  
 
Fluorescent Imaging 
Fresh-frozen organs were sectioned on a cryotome with a thickness of 3-5 µm, mounted to 
Superfrost Plus microscope slides and fixed for 30 min in 4% paraformaldehyde (PFA) at 
room temperature (RT) followed by three washes in PBS. At this point, some samples were 
set aside for IMC staining and imaging on the Hyperion system (Run 4 in section 5.3, protocol 
described in section 1.2.3). For cryosections undergoing fluorescence imaging, slides were 
stained with 10 µg/mL Hoescht 33342 (Thermo) in PBS for 30 minutes at RT, then destained 
in PBS for 30 min at RT, before being mounted with glass coverslips using Fluoromount AG 
and imaged on an Olympus VS120 slide scanner at 10X resolution (0.6493 µm pixel diameter), 
using the DAPI (blue) and FITC (green) channels to measure DNA (Hoescht stain) and eGFP, 
respectively. 
 
Whole-mounted mammary glands were immediately fixed in 4% PFA for 1.5h at 4°C, then 
cleared in 50% (v/v) glycerol/PBS for 4 hrs at room temperature (RT). Samples were then 
placed in 50% glycerol/PBS containing 10 µg/mL Hoescht 33342 (Thermo) and stained 
overnight at RT with mild agitation. The next day, samples were destained for 1h each in 50%, 
75%, and 100% glycerol in PBS, respectively, with mild agitation. A coverslip was mounted 
on each sample slide with glycerol and the sample was compressed to flatten out the tissue as 
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much as possible before imaging. Fluorescent images of the cleared and stained whole-
mounted mammary glands were immediately acquired on an Olympus VS120 slide scanner at 
10X resolution, using a 50 µm EFI scan depth and the same fluorescence channels mentioned 
above. Since there were many blurry areas in the first acquisition, a second acquisition was 
performed that used the FITC channel instead of the DAPI channel for autofocusing.  
 
In order to capture more spatial information from the 3D structure of the whole mounted 
glands, the instrument software (VS-AWS) utilizes a technique known as extended focal 
imaging (EFI) which acquires images from multiple focal planes (z-depth) above and below 
the autofocus plane, extracts the most in-focus areas from each focal plane using an edge-
finding algorithm, and stiches them together into a single image. This is done separately for 
each field of view, called a “tile”, and the resulting tiles are stitched together into the final 
output image. Due to the resolution and size of the stitched 10X image, it is too large to be 
viewed in its entirety on most computers (requires too much RAM). Thus, images are exported 
as a virtual slide image (.vsi file format), which uses an indexed hierarchy of image stacks at 
compressed resolutions so that the highest resolution is only loaded when zooming into a small 
area. Among the few open-source programs that can handle and interpret these files, QuPath 
(v0.2.0-m1) was chosen due to its speed and cell detection modules [65]. QuPath was used to 
estimate the number of GFP+ cells in lung and spleen cryosections and whole mounted 
mammary gland as a proportion of the total number of cells. First, all cells were detected by 
their Hoescht-stained nuclei (in the DAPI channel) using the cell detection molecule (default 
parameters) and a nucleus expansion of 5 µm to mark the cell membrane boundary. Next, 
positive cells were detected using the “select objects by measurement” module, excluding cells 
in regions near autofluorescent artifacts (hairs and bubbles). The measurement parameters 
were empirically determined based on the ability to discriminately select a subset of manually-
identified positive cells, and set as “Cytoplasm: FITC channel max > 800 AND Cytoplasm: 
FITC channel mean > 400”. 
 
Lung and mammary dissociation and flow cytometry 
Mammary gland and lung samples from the aforementioned dissection were thoroughly 
minced in PBS and subjected to specialized dissociation protocols that were previously 
established in-house. Minced lung lobes were transferred to a gentleMACS C tube (Miltenyi 
Biotech) containing 2.6 mL of dissociation buffer (5 mL Hank’s buffered salt solution (HBSS) 
with 10mM HEPES, 75 µg/mL Liberase (Roche), and 20 µg/mL DNase I (Stem Cell 
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Technologies)) and dissociated on the gentleMACS Dissociator (Miltenyi Biotech) with the 
program “m_lung_01”, followed by a 30 min incubation at 37°C with inversion every 5 min 
and the program “m_lung_02”. The dissociated cell/tissue solution was strained through a 70 
µm filter which was then rinsed with an additional 2.5 mL dissociation buffer. The cells were 
washed twice with 5 mL PBS by centrifuging at 300 g for 10 minutes and resuspended in 3 
mL MilliQ water for flow cytometric analysis. Minced mammary glands were transferred to a 
50 mL falcon tube containing 2 mL of 12.5 mg/mL collagenase and 13 mL Epicult-B Mouse 
medium with supplements (StemCell Technologies, cat. #05610) and incubated for 4 hrs at 
37°C with gentle shaking. The resulting slurry was vortexed and triturated with a pipette and 
cells were collected by centrifuging at 150 g for 5 min at RT and discarding the supernatant. 
The pellet was resuspended with 10 mL of a cold 1:4 mixture of HBSS with 2% FBS (HF 
buffer) and Ammonium Chloride Solution (StemCell, cat. #07850) to lyse residual red blood 
cells and centrifuged at 450 g for 5 min at RT. The supernatant was discarded and the pellet 
was resuspended in 2 mL pre-warmed 0.25% Trypsin-EDTA (Sigma) and mixed with a pipette 
for 3 min to release single cells, which were then washed by adding 10 mL HF buffer, 
centrifuging at 150 g for 5 min at RT, and removing the supernatant. The pellet was mixed for 
1 min with 2.2 mL of prewarmed HBSS with 5 mg/mL Dispase with 0.1 mg/mL DNase I 
(StemCell, cat. #07913/07900) to digest free ECM proteins and DNA, respectively, and 
diluted in 10 mL cold HF buffer before filtering through a 40 µm cell strainer into a new 50 
mL falcon tube. The single cell solution was centrifuged at 450 g for 5 min at RT, the 
supernatant was discarded and the pellet was resuspended in MilliQ water for flow cytometric 
analysis.  
 
Dissociated lung and mammary cells were analyzed on an Accuri C6 flow cytometer (BD 
Biosciences), using the FL3 and forward and side-scatter detectors to detect GFP and single-
cell events, respectively. One million events were collected per sample. To determine the 
stability of the fluorescent GFP signal, the remaining lung cells were split into two groups: 
one untreated and left in light, and another fixed in 4% PFA and protected from light, which 
were analyzed 4 hrs later. Flow cytometric data was analyzed in FlowJo software (v10.6.1). 
4.1.4 Axl-LacZ mouse model 
The B6.129P2-Axltm1Dgen/J mouse strain, which is homogenous for the Axl-LacZ insertion 
(from section 2.1.2) was purchased from the Jackson Laboratory (stock # 005777) for previous 
experiments in our group. The strain was originally generated by Deltagen, Inc. by introducing 
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the LacZ gene and an FRT-flanked neomycin resistance cassette into exon 11 of the mouse 
Axl gene using homologous recombination in ES cells in a similar fashion as the Axl-CreERT2-
EGFP strain. Previously, organoids were grown from mammary cells isolated from Axl-LacZ 
HET and Axl-LacZ KO mice using the same dissociation protocol described above. Cells were 
labeled using a commercial FDG reporter kit (FluoReporter® 469 lacZ Flow Cytometry Kit, 
Molecular Probes cat. #F-1930) following the manufacturer’s protocol and sorted by a FACS 
ARIA (Becton Dickinson) cell sorter into FDG-(Axl)-low and -high samples, which were then 
seeded in Matrigel and cultured into organoids for approximately 2 weeks. Sections of 
formalin-fixed paraffin embedded (FFPE) lung, mammary glands and organoids were IF 
stained (using antibodies against K5, K8 and/or β-gal with DAPI nuclear stain).  X-gal staining 
was performed on some organs prior to FFPE, sectioning, Eosin counterstaining, and 
brightfield imaging. In the current work, these same FFPE samples were sectioned and 
analyzed with IMC (Run 2/5 in Section 5.3).  
4.1.5 4T1 mammary tumorigenesis model 
BALB/c mice were orthotopically injected with 4T1 breast cancer cells as part of another 
study. Tumors developed under the skin, and mice were monitored daily and sacrificed when 
their tumor volume reached the cutoff value set for the study. One FFPE tumor from this 
study was used in Run 3 of the IMC experiments.  
4.2 IMC 
4.2.1 Antibody Conjugation 
All in-house conjugations were performed using MaxPar Antibody Labeling Kits (Fluidigm), 
which contain polymer, loading buffer (L-buffer), reduction buffer (R-buffer), conjugation 
buffer (C-buffer) and wash buffer (W-buffer), following the manufacturer’s protocol. Unless 
otherwise mentioned, all centrifugation steps were performed at 12,000 g at RT and flow-
through from the spin columns was discarded when necessary. MaxPar X8 polymer was 
equilibrated to RT, dissolved in 95 µl L-buffer and 5 µl of the specified lanthanide (heavy 
metal) ion solution and incubated for 30 min at 37°C in a heat block. Meanwhile, the 
concentration of the antibody to be conjugated was measured on a Nanodrop 2000 
spectrophotometer (Thermo Scientific). If the antibody was originally in glycerol, the stock 
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solution was filtered through a 50 kDa spin filter (Amicon) and resuspended in the initial stock 
volume of PBS before measuring. A calculated volume of antibody equivalent to 100 µg (or 
the entire volume if <100 µg in total) was added to a 50 kDa filter along with 300 µL R-buffer 
and spun down for 10 min. The antibody was reduced by adding 100 µL of 8 mM TCEP 
(Thermo) in R-buffer and incubating for 30 min at 37°C. The metal-loaded polymer was 
transferred to a 3 kDa filter, diluted in 200 µL L-buffer and spun down for 25 min, and washed 
again by resuspending in 400 µL C-buffer and spinning down for 30 min. The antibody 
reduction was quenched by adding 300 µL C-buffer and spinning down for 10 min, and 
washed by resuspending in an additional 400 µL C-buffer and spinning down for 10 min. The 
metal-loaded polymer was resuspended in 80 µL C-buffer and transferred to the 50 kDa filter 
with the reduced antibody and incubated for 90 min at 37°C in a heat block to conjugate the 
antibody. Following conjugation, the antibody was washed and the polymer was removed by 
adding 200 µL W-buffer and spinning down for 10 min, with an additional three wash cycles 
of 400 µL W-buffer. The conjugated and purified antibody was resuspended in 100 µL of W-
buffer and quantified via Nanodrop in order to calculate the volume of antibody stabilizer 
(CANDOR Bioscience) needed to elute the antibody at a concentration of 0.5 mg/mL. After 
removing the W-buffer by spinning down for 10 min, the calculated volume of antibody 
stabilizer was added and the filter was inverted, placed in a new collection tube and collected 
via centrifugation at 1000 g for 2 min. The conjugated antibody was stored at 4°C in the dark 
until use.  
4.2.2 Generation of 4T1 control cell pellets 
In order to produce mock tissue samples for IMC testing that served as positive controls for 
important markers such as Axl and GFP, cells were cultured, fixed and embedded in pellets. 
4T1 BALB/c breast cancer cells were previously harvested, and the GFP gene was inserted 
into exon 11 of the Axl gene using CRISPR-Cas9 gene editing as previously described [66], 
serving as a functional Axl knockout while expressing functional GFP. All cell culture steps 
were performed in a sterile laminar airflow hood, and the incubator was always set to 37°C 
with 5% CO2 and 21% O2. One million 4T1 and 4T1 Axl-KO-GFP cells each were seeded in 
T75 flasks and cultured in 10 mL cell culture medium (RPMI1640 with 10% FBS, 2 mM L-
glutamine, 100 U/mL penicillin and 100 µg/mL streptomycin, all from Sigma) in an incubator. 
When the cells reached 80-90% confluency, they were trypsinized with 5 mL pre-warmed 
0.25% Trypsin-EDTA, quenched with 10 mL cell culture medium, centrifuged at 290 g for 7 
min at RT, and split into 2 T175 flasks containing 20 mL cell culture medium. This process 
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was repeated again in order to grow 4 confluent T175 flasks each of the two cell types, which 
were trypsinized, pelleted by centrifugation (same settings) in a 50 mL conical tube, and 
resuspended and fixed in 5 mL 4% PFA for 1 hr at RT. After a brief (2 min) stain with 40 µL 
methyl green, cells were washed twice by adding 15 mL PBS, centrifuging and removing the 
supernatant. The resulting cell pellets were gently but thoroughly resuspended in 60 µL human 
blood plasma, to which 30 µL of 100U/ml thrombin was added and mixed. After incubating 
for 20 min at RT to allow coagulation to occur, the resulting pellets were carefully removed 
from the bottom of the tube and securely placed in plastic tissue embedding cartridges and 
submerged in 4% PFA until embedding in paraffin the next day. The resulting tissue blocks 
were sectioned for IMC analysis.  
4.2.3 Sample preparation workflow 
Fresh-frozen and FFPE tissue blocks were sectioned at 5 thickness on a cryotome or 
microtome, respectively, mounted on SuperFrost Plus microscope slides and stained with 
metal-conjugated antibodies per Fluidigm’s suggested protocol for Hyperion analysis 
(Protocol ID PN 400322 A3). All solutions were made with MilliQ water and kept in plastic 
bottles to avoid heavy metal contamination, and all washes were performed in 50 mL conical 
tubes at RT with gentle agitation. Briefly, FFPE tissue slides were baked for 2 hrs at 60°C to 
remove as much wax as possible before dewaxing in consecutive xylene solutions for 2 x 10 
min, followed by rehydration in descending grades of ethanol (100%, 95%, 80%, 70%) for 5 
min each. Serial sections for H&E staining (if required for the experiment) were then 
separated, processed according to standard protocols [67], and imaged on the Olympus VS120 
slide scanner at 10X resolution. Slides for IMC analysis were then washed in MilliQ water for 
inserted in 50 mL conical tubes containing preheated antigen retrieval (AR) solution (10mM 
Tris Base, 1mM EDTA, 0.05% Tween 20, pH 9.0) and incubated at 96°C for 30 min in a hot 
water bath. The tubes were removed from the bath and allowed to cool to 70°C before washing 
twice with MilliQ water and twice with PBS. To prevent nonspecific binding of antibodies to 
tissue or Fc receptors, tissue sections were encircled with an ImmEDGE hydrophobic barrier 
pen (Thermo) and covered with a solution of 3% BSA in PBS in a hydration chamber for 1 hr 
at RT. During this blocking step, a cocktail of metal-conjugated antibodies was prepared by 
adding the calculated concentration of each conjugate to a small volume of 3% or 10% BSA 
in PBS (depending on whether the total amount of antibody added was >83% of the desired 
cocktail volume) and diluting in PBS to a final BSA concentration of 0.5%. Detailed lists of 
all antibodies used in each experiment can be found in section 5.3. If the cocktail preparation 
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took longer than 1 hr, the BSA blocking step was ended by submerging the samples in PBS 
until the cocktail was ready. The sections were then covered with antibody cocktail solution 
(~50-75 µL per 10 mm2 section) and stained overnight in a hydration chamber at 4°C. The 
next day, sections were washed twice in 0.2% Triton X-100 in PBS and twice in PBS for 8 
min each for a total of 4 washes. The sections were then covered and stained with Iridium 
DNA intercalator (Cell-ID™ Intercalator-Ir, Fluidigm cat. #201192A) for 20-30 min in a 
hydration chamber at RT, washed for 5 min in MilliQ water, and air-dried for at least 20 min 
before analyzing on the Hyperion instrument. Fresh-frozen sections from section 1.1.3 were 
processed with the same protocol, starting at the AR step. 
4.2.4 Hyperion instrument setup and operation 
If the instrument was initially in SMC mode (Helios only), the Hyperion module was carefully 
positioned using an alignment tool such that the coupling tube fed orthogonally into the sample 
inlet (Fig 2.4). Next, the argon and helium gas valves were opened and the plasma coil was 
turned on. A 3-Element Full Coverage Tuning Slide (Fluidigm, PN 201088) was loaded onto 
the slide stage, the laser was turned on and autotuning was performed, which optimizes the xy 
calibration of the plume path and the flow of the helium gas that carries the plume to the 
detector and gives a general indication of the instrument sensitivity, which must be >500 
Lu(175) counts/plume and ideally >1000 counts/plume. Next, a crude image of the sample 
slide was acquired on a smartphone and uploaded in the HTI acquisition module, and the slide 
was loaded onto the sample stage. Panoramas were taken of the sample slide based on the 
tissue locations of interest on the crude image, taking into account any potential xy offset 
between the crude image and the actual sample position. The laser intensity was then calibrated 
by choosing a non-relevant area of tissue to ablate at different intensities, and setting the laser 
intensity such that all of the sample was ablated but the glass underneath was not being burned. 
Next, ROIs were selected on the panorama images of the sample based on guidance from serial 
H&E/fluorescent images or a general indication of what tissue region was relevant. An 
acquisition template including all metals utilized in the panel along with their corresponding 
markers, the desired laser intensity and ablation frequency (always 200 Hz) was created and 
assigned to all ROIs, which were then ablated and the resulting multiplexed images were 
exported as an .mcd file.  
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4.2.5 Data analysis pipeline 
Exported IMC data was opened in MCD Viewer software (Fluidigm, v1.0.560), and the 
staining quality of each antibody was subjectively evaluated and annotated for each ROI and 
tissue type based on the signal intensity (auto threshold max), presence of aggregates, +1/-1 
channel spillover, and expected staining pattern inferred from the literature (IHC/IF 
applications) and colleagues. Based on this information, markers were chosen to export as 
.ome.tiff images for downstream analysis. The folder of exported images was then loaded into 
the data analysis pipeline in CellProfiler (Broad Institute Inc., v2.2.0). In some instances, 
thresholding was applied on channels containing aggregates to eliminate unnatural high-
intensity pixels. The signal intensities of the two Iridium DNA intercalator isotopes and 
selected cytoplasm/membrane markers (if available) were combined and scaled for visibility 
using the ImageMath function into a “DNA” image and a “Cellular” image, respectively. 
Nuclei were identified using the IdentifyPrimaryObjects function with “DNA” as the input 
image and cells were identified using either the IdentifySecondaryObjects function with a 1 
pixel (1 µm) expansion from the nucleus or, if structural markers were available, using the 
“Cellular” image in IdentifyPrimaryObjects. Cytoplasm was identified using the 
IdentifyTertiaryObjects function, which selects objects between the cell and nucleus outlines. 
The parameters affecting the performance of these functions were empirically determined for 
each sample type and are outlined in section 5.3. The nuclei, cell, and cytoplasm objects were 
each converted into image masks (uint16 color format) and saved in the same folder as the 
original images exported from MCD Viewer as .ome.tiff files. The folders containing staining 
images and masks for each ROI in an experiment were imported into histoCAT 
(Fluidigm/Bodenmiller Lab, v1.76). In histoCAT, the cells in each image were clustered and 
visualized based on their staining intensity values for each marker using phenograph and 
tSNE, respectively. Segmentation parameters were sometimes recursively adjusted based on 
these data. When applicable, neighborhood analysis was performed to characterize interaction 
frequencies between cells [68]. 
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5. Results 
5.1 Genotyping optimization and troubleshooting 
Table 5.1: Genotyping optimization of Axl-CreERT2-EGFP Rosa26-Flp/TdTomato mice. Each run is identical to the one 
above it except for the changes listed in the “variables tested” column. All mice were homozygous for the Axl-CreERT2-
EGFP knock-in (Axl-KI) construct. Detailed thermal cycle conditions for each PCR protocol can be found in Table 3.4. The 
Standard and Ozgene protocols utilize a gradient PCR, meaning that each sample was tested over a range of annealing 
temperatures in 8 identical reactions. Each gel result represents testing of at least 2 mice with the same reported genotype 
(according to Ozgene). MMX: master mix; FLP: Rosa26-Flp allele; TdT: Rosa26-TdTomato allele; NSP: nonspecific PCR 
product.  
The general strategy employed for genotyping assay optimization was to start with our current 
in-house genotyping protocol and modify various PCR conditions such as sample input 
volume, thermal cycle conditions, polymerase type or mastermix components until distinct 
PCR products matching the expected size could be amplified from the corresponding positive 
control samples and visualized by gel electrophoresis, using separate conditions for each target 
allele if deemed necessary. Typically this is not required for endpoint genomic PCR assays as 
they are quite robust, however in this case an extensive optimization was carried out due to 
the inability to initially detect the Flp and TdTomato transgenes. A summary of the initial PCR 
genotyping assay optimization experiments can be found in Table 5.1.  
In summary, the Axl-CreERT2-EGFP knock-in allele was detected in all mice tested, across 
all PCR conditions, and no Axl-wt products were ever observed, since all mice were 
homozygous for the knock-in mutation. The Rosa26-Flp allele was only able to be detected 
when betaine was added to the mastermix, and thus required its own assay protocol. The 
Rosa26-TdTomato allele, however, was not detected in any of the optimization experiments 
performed, despite extensive testing of many different mastermix/enzyme formulations (e.g. 
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KlearKall, Thermo Phusion, NEB Q5) with both gradient and touchdown PCR protocols. One 
notable run using a very robust PCR protocol with Phusion polymerase (400-fold increased 
sensitivity over Taq polymerase) and touchdown PCR (cycles with incrementally lower 
annealing temperatures to ensure the target sequence is amplified) showed that the Jackson 
TdTomato primers could amplify many nonspecific products from the two Ozgene 
TdTomato/wt lysates but not TdTomato, strongly  indicating that the target sequence was not 
present (Figure 5.1).  
This prompted us to consider one of two possibilities: 1) our protocol (either the lysis or the 
PCR itself) was suboptimal; or, 2) the mice did not harbor the TdTomato reporter allele. A 
collaborator at University of Oslo (UiO) Cancer Center (Dr. Jens Henrik Norum’s group) also 
used the same TdTomato reporter mice and routinely genotyped them in their lab. Therefore, 
we brought our old lysates from the original Ozgene TdT/Wt mice and fresh, unlysed ear 
samples from their offspring to UiO and ran them through our collaborators’ lysis and 
genotyping protocol (same Jackson labs primer sequences, ampliTaq Gold polymerase, and 
the Alternative PCR thermal cycle conditions) alongside some lysates from their lab that they 
had previously confirmed were positive for TdTomato (Figure 4.2). The positive control 
samples were brought back to our lab and the results were confirmed in an independent 
experiment using the same protocol (data not shown). 
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Figure 5.2: PCR genotyping results of Ozgene mice and their offspring run alongside positive controls for 
Rosa26-Wt and TdTomato at UiO. Samples were analyzed with both TdTomato and Wt primers in a single PCR 
reaction. Positive control samples from previously confirmed TdTomato (red) and WT (blue) homozygous mice show 
PCR products with distinctly different sizes corresponding to the expected product size from each primer set. Samples 
from the original Ozgene mice allegedly heterozygous for TdTomato (purple) only showed Wt product bands, while 
the offspring of these mice (yellow) showed only Wt bands or no band at all.  
 
These data further confirmed the lack of TdTomato in the mice we received from Ozgene. 
However, the fact that some of the offspring lacked a Wt product was indicative of a cross 
between two heterozygous mutants, prompting us to consider if the identity of the samples 
taken from the original Ozgene mice were somehow mismatched (due to the complex 
earmarking codes used by Ozgene) and that the Rosa26-FLP mice were accidentally used for 
breeding. Therefore, all mice received from Ozgene were carefully resampled, lysed, and 
tested in Bergen using fresh TdTomato, Flp and Wt primers (Jackson) ordered through the 
same vendor that was used in Oslo (data not shown). This run confirmed that the samples were 
not mismatched. After communicating our concerns to Ozgene, they responded by noting that 
they have been successfully maintaining the Axl-CreERT2-EGFP-Rosa26-Wt/TdTomato strain 
at their facility using an in-house real-time PCR (rt-PCR) assay. Although this strategy 
measures the cumulative cleavage of a fluorescent reporter from a probe sequence targeting a 
midpoint region between the forward and reverse primers to quantify target amplification, 
these primers should still produce an end product detectable by gel electrophoresis. Therefore, 
these primers (last row in Table 3.2) were ordered and tested on the Ozgene and positive 
control lysates with endpoint PCR using the same protocol as the prior two runs (data not 
shown). Even using the primers that Ozgene recommended to genotype the strain, we could 
not detect TdTomato in any of the original mice received from Ozgene, while the primers 
clearly worked for the two positive TdTomato control samples from UiO. All of the 
aforementioned genotyping data was compiled into a report and sent to Ozgene in August, and 
all experiments regarding the Axl-CreERT2-EGFP-Rosa26-Wt/TdTomato mice, including 
lineage tracing and organoid studies, were put on hold.  
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5.2 Characterization of mouse models 
While the genotyping optimization was taking place, the Axl-CreERT2-EGFP-Rosa26-Wt 
mice were used in experiments to measure and confirm Axl-GFP coexpression in various 
tissues. These experiments were performed to test the feasibility of the various analytical 
techniques required to evaluate the Axl-GFP strain and the planned lineage tracing study, 
while organoid experiments were rather conducted in the established Axl-LacZ strain.  
5.2.1 Whole-mount mammary imaging 
The whole-mounted mammary fluorescence image acquired in Section 4.1.3 from a 12-week-
old female Axl-CreERT2-EGFP mouse was analyzed both subjectively and quantitatively to 
determine the presence of GFP+ cells. Visual inspection of the image in QuPath revealed two 
distinct patterns of expression: rare isolated GFP+ cells located in either the stroma or the 
mammary epithelia (Figure 5.3A), and ubiquitous GFP expression by endothelial cells lining 
the lymphatic ducts. These ducts drain to the lymph node at the center of the mammary gland, 
whose strong green fluorescence can be attributed to either the presence of Axl-GFP+ immune 
or endothelial cells in the node, or autofluorescence. It was difficult to ascertain the three-
dimensional location of the rare GFP+ cells in relation to the mammary ducts, and therefore 
no conclusion could be drawn as to whether these cells were in fact the rare suprabasal Axl+ 
progenitor cells we were looking for in this strain. The QuPath analysis modules mentioned 
previously were used to quantify both the total number of cells (nuclei) and number of GFP+ 
cells, which were 496,179 and 828 cells, respectively, meaning the proportion of GFP-positive 
cells was ~0.17%. It is important to note that only discrete GFP+ cells were detected (like 
those in Figure 5.3A), while excluding endothelial cells.  
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Figure 5.3: Fluorescent EFI scan of a whole-mounted Axl-CreERT2-EGFP mouse mammary gland. (A) 
Rare putative Axl-GFP+ cells located near or within mammary epithelial ducts (1-2) and at a cluster at the edge 
of the gland area (3). (B, C) GFP was ubiquitously expressed by lymphatic endothelial cells, which are well-
visualized by the EFI technique. Blue: hoechst DNA stain; green: GFP. 
 
5.2.2 Fluorescent cryosection imaging 
Spleen and lung cryosections from the same mouse pictured above are shown in Figure 5.4A 
and B, respectively. Although GFP+ immune cells are clearly distinguishable in both pulps of 
the spleen, the expression of GFP was more uniformly scattered in the alveoli with some rare 
cells showing more intense, point-like GFP expression. Referencing basic lung histology 
(Figure 5.4C) [69] and prior X-gal staining of Axl-LacZ-HET mice in our group (Figure 5.4D) 
suggested that the GFP expression pattern was indicative of Axl+ type 2 lung cells and 
endothelial vessel cells.





Figure 5.4: GFP expression in lung (A) and spleen (B) cryosections from an Axl-CreERT2-EGFP 
mouse. Magnified regions of whole-organ scans denoted with (1). (C) Reference illustration of the lung 
alveolar functional unit, comprising of thin type 1 (ATI) and secretory type 2 (ATII) epithelial cells with 
resident macrophages and fibroblasts. (D) Brightfield image of alveoli from Axl+/LacZ (Axl-LacZ-HET) mice 
immunohistochemically stained for Pro-SP-C (an ATI marker) and stained with X-gal to detect the β-gal Axl 
reporter and eosin counterstain. C adapted from [68] and D from Lorens lab. 
 52
5.2.3 Flow cytometry of mammary and lung cells 
The ability to detect GFP+ cells from the same mouse in the preceding experiments was 
determined by flow cytometric analysis of dissociated mammary gland and lung cells. The 
quantification of GFP+ cells in both samples is shown in Figure 5.5.  
 
Figure 5.5: Gating and quantification of a subset of GFP+ cells from dissociated Axl-CreERT2-EGFP 
mouse mammary gland (A) and lung (B) tissue analyzed by flow cytometry. Single cells were separated from 
debris and doublets by gating on a plot of forward scatter area (FSC-A) versus side scatter area (SSC-A). A 
distinct GFP+ population was visible in both samples when plotting single cells on a graph of fluorescence 
channel 1 (FL1, detects GFP) area versus SSC-A. This population was gated and quantified as a percentage of 
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5.3 IMC 
The results of each IMC experiment are systematically and chronologically presented below. 
For each run, the underlying rationale for the experiment will be briefly presented, followed 
by any supporting H&E or IF images that were used to guide ROI selection. Next, a table 
summarizing each antibody used in the experiment is provided, that states the purpose of each 
marker, the source of the antibody (referred to as a “clone” if it is monoclonal in origin) and 
which heavy metal it was conjugated with, the relative confidence that the antibody would 
work in the given sample type (on a scale of 1-3) and the reasoning supporting this rating, the 
concentration tested, whether the overall staining quality was unacceptable (-), acceptable (+), 
excellent (++), or not conclusive (NC) and in which tissues, possible reasons why the staining 
didn’t work if the quality was (-) or (NC), and any issues observed in the particular channel 
either directly associated with the antibody staining or resulting from neighboring channels.  
 
The confidence score was based on the following scale: 3, previously tested in-house showing 
strong staining or validated by Fluidigm on the Hyperion system; 2, indications from the 
literature or manufacturer that the antibody worked on the sample type being analyzed (frozen 
or FFPE) or previous testing showing weak staining; 1, no indication of successful application 
in the given tissue type from any source. All experiments were performed on mouse cells or 
tissue, and all antibodies were stated by the manufacturer to be reactive against the murine 
ortholog of the target protein. The concentrations of all pre-conjugated IMC/CyTOF 
antibodies from Fluidigm were initially unknown (since a standard volume of 1 µL per million 
cells is recommended for CyTOF), and some but not all of the concentrations were eventually 
obtained from Fluidigm. For those antibodies whose concentration was still unknown, a rough 
assumption was made based on the known range of Fluidigm conjugate concentrations and 
the general intensity of expression of a given target protein (which is inversely correlated with 
the conjugate concentration), and these assumed concentrations are marked in bold/italics. 
Any markers with (+) or (++) staining in a given tissue were included in downstream analysis. 
A general description is given of the outcome of the experiment, including any overarching 
issues encountered, and representative images of particularly notable combinations of marker 
staining are shown for each tissue (the black-and-white images of every channel recorded in 
each experiment for representative ROIs are listed in an appendix, see section 10). Finally, the 
data analysis steps performed for each tissue type are described with accompanying figures.  
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5.3.1 Run 1: FFPE cell pellets 
In order to test several key antibodies on control samples that were either positive or negative 
for specific markers and to evaluate the Hyperion workflow for the first time, sections of FFPE 
4T1 WT and AXL-KO-GFP cell pellets (from section 4.2.2) were stained with a 2-fold 
titration (dilution) series of the antibody cocktail described in Table 5.3.1 (the concentration 
column represents the starting concentrations in the dilution series, denoted T4, and the 
dilutions are denoted as T3-T1 in descending order of concentration). A section of each cell 
type was also stained with a solution containing no antibodies (T0) to observe background 
signal. No supporting H&E images were required to guide ROI selection, since the samples 
were homogenous and any region could be selected on the pellet area at random. 
 
Figure 5.3.1A. IMC images of 4T1 Axl wild-type (WT) or -GFP+-knockout (KO) cell pellets stained with 
a cocktail of heavy metal-conjugated antibodies. Matching samples of KO and WT cell pellets (from the same 
cocktail titration) are shown, with DNA and Axl staining in one image and PD-L1, MerTK, and GFP in another 
image of the exact same ROI from left to right. The rightmost image shows another KO pellet section stained 
with PBS/BSA only (no antibody).  
AXL staining was evident in both the WT and KO cells, while staining of all other markers 
was not detected, as only noise (random single antibodies not washed from the slides) was 
visible in these channels (Figure 5.3.1A). It is unclear whether the cells did not express these 
proteins or that the staining was ineffective.  
When viewed and exported from MCD viewer, the default pixel intensity range of each 
channel in the IMC image is automatically set such that the maximum intensity corresponds 
Table 5.3.1: List of antibodies used in Run 1. Cellular location refers to what part of the cell the marker should be found. LIG, 
ligand (cytosolic or extracellular); EC, extracellular; CYT, cytosolic; MEM, membrane. The staining confidence score is on a 
scale of 1-3. Reasons behind the confidence score are: LIT, from the literature; NI, no indication. For markers that did not show 
positive staining, possible reasons include: CTNP, cell type not present; NSB, non-specific binding. Refer to the HUGO 
guidelines for all target abbreviations. 
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to the 95th percentile of pixel counts for the given heavy metal per image, known as “auto 
threshold counts”. As a general rule of thumb, the conjugate staining quality can be considered 
too weak for recommended use if the auto threshold counts are below 5, since the positive 
signal from the antibody at this level usually cannot be distinguished from the noise resulting 
from random nonspecific antibody binding. This noise increases with increasing antibody 
concentration, as shown in Figure 5.3.1B.  
Figure 5.3.1B: Distributions of mean single-cell metal counts from 4T1 WT pellets stained with a titration 
series of conjugated antibody cocktail. The noise contributing to nonzero cell intensities is roughly correlated 
with increased antibody concentration (T1-T4). Data generated with HistoCAT. 
 
The mean cell counts are zero or very close to zero for the T0-stained pellets, indicating that 
most of the random noise in each metal channel is due to the presence of residual conjugates 
and not from heavy metal contamination of the sample or instrument. In order for the single 
cell intensity to be measured, cell segmentation must be performed on the images, which was 
done using the default settings in the IdentifyPrimaryObjects function in CellProfiler to 
generate a cell mask for each image (Figure 5.3.1C). For such quantitation measurements to 
be proportional, the nuclei of the cell population being measured must be fairly homogenous, 
which was not the case with the 4T1 knockout cell pellet sections (Figure 5.3.1D).  
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Figure 5.3.1 C&D. (C) (left) representative cell mask image generated from DNA stain images in CellProfiler 
overlaid on the sample image with several markers shown in color. (D) (right) Distribution of nuclear areas 
from cell segmentation in each sample (from left to right: KO T1-4, WT T-14). Data generated with HistoCAT. 
The Axl cell staining intensity was also correlated with increased antibody concentration 
(Figure 5.3.1E), and since the auto threshold counts were above the cutoff value and a distinct 
staining pattern was observed, this can be considered as true antibody signal. However, this 
signal may arise from nonspecific binding of cellular regions since the same staining pattern 
was observed in the supposedly Axl-null cells. Moreover, since two Axl-targeting clones were 
tested in the same metal channel (a strategy often employed to enhance sensitivity to a low-
abundance antigen), the performance of either individual antibody could not be distinguished.  
Figure 5.3.1E: Distributions of mean single-cell 176Lu-Axl counts from 4T1 WT pellets stained with a 
titration series of conjugated antibody cocktail. Data generated with HistoCAT. 
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5.3.2 Run 2: FFPE mammary gland and lung 
Since the cell pellet experiments were inconclusive and likely not indicative of the staining 
quality in FFPE tissue, an IMC antibody cocktail was then tested on the target tissues of the 
intended stem cell panel: mouse mammary and lung. A list of all antibodies used in the cocktail 
and their staining results is shown in Table 5.3.2. 
Many pre-conjugated antibodies were available from our existing inventory of CyTOF clones 
and were evaluated for their feasibility in IMC. In order to guide ROI selection on the sample 
panoramas acquired by the Hyperion, serial (coming from the section directly above or below 
the IMC-stained section) H&E images of Axl-wild type and Axl-LacZ-KO mammary and 
wild-type lung tissue sections were acquired and are shown in Figure 5.3.2A. 
Table 5.3.2: List of antibodies used in Run 2. Cellular location refers to what part of the cell the marker should be found. LIG, 
ligand (cytosolic or extracellular); EC, extracellular; CS, cytoskeleton; CYT, cytosolic; MEM, membrane. The staining 
confidence score is on a scale of 1-3. Reasons behind the confidence score are: NI, no indication; LIT, from the literature; UV, 
Hyperion user-validated; SSA, supplier-suggested application; HVA, Hyperion-validated antibody; PT-S, previously tested--
strong staining. For markers that did not show positive staining, possible reasons include: CTNP, cell type not present; NSB, 
non-specific binding; CTL, concentration too low. Staining issues include: DA, direct aggregate (from antibody in channel); 
NCA, neighboring channel aggregate. “+” signs indicate the issue is more pronounced (2-fold increase per “+” sign). Refer to 




Figure 5.3.2A: Serial H&E images of Axl-Lac-KO mammary gland (A) and Axl wild-type mammary gland 
(B) and lung (C). ROIs for IMC ablation containing ducts and other tissue compartments were selected on 
mammary sections, while ROIs containing alveolar compartments and upper respiratory airway structures were 
selected on lung sections. 
Representative IMC images of notable marker combinations in each tissue are shown in Figure 
5.3.2B. In general, very few of the IMC antibodies showed positive staining in either of the 
tissues tested, which could be because many of the antibodies targeted antigens not highly 
expressed in either tissue due to the cell type not being present, particularly in the (relatively 
small) ~100 µm2 ROIs selected. Another possibility is that the assumed concentrations of 
many of the antibodies were too low, and not enough was added to the cocktail. Additionally, 
many high-intensity aggregates were observed, some of which were a single pixel in diameter 
while others seemed to colocalize to specific points, indicative of dust contamination.  
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Figure 5.3.2B: Representative 
IMC images of notable 
markers in each tissue type. 
Upper left: pulmonary vessel in 
lung, upper right: bronchioli 
structures with basal and 
epithelial markers. Middle: 
mammary duct with basal and 
luminal markers (red: K5/6, 
green: K19). Bottom: mammary 
duct with epithelial and immune 








Figure 5.3.2C: Cell segmentation of mammary duct cells with or without exponential transformation of 
the DNA image. Segmentation of the untransformed DNA image (top) results in the inability to segment the 
majority of the epithelial cells in the mammary duct using many thresholding settings, resulting in large objects 
(purple) that are discarded because they are outside of the accepted size range. Raising the pixel intensity to a 
power of 1.5 (bottom) significantly enhances segmentation of these cells (green, accepted objects) while 
maintaining the ability to identify most of the dimmer cells outside of the duct. Data generated in CellProfiler. 
Despite the relatively low success rate of the antibodies tested, there were still an adequate 
number of successful markers for different cell types in each tissue to justify downstream data 
analysis and confront the challenges therein. In MCD viewer, multiple markers with 
nonconclusive staining results were also exported with the primary markers to see how their 
incorporation would affect the core tSNE/phenograph analysis. The first and often primary 
challenge in IMC data analysis is cell segmentation. Fluidigm suggests that Hyperion users 
start with the default/automatic settings in the IdentifyPrimaryObjects module (using a 
expected nuclei diameter range of 5-15 pixels), so this was tested first. Although this appeared 
to work reasonably well for lung alveoli, where epithelial nuclei of ATI/II cells are fairly well-
separated, the epithelial nuclei in the mammary ducts are small and tightly packed together, 
making them difficult to segment. Indeed, many iterative adjustments of the various 
segmentation parameters such as min/max diameter, thresholding method, and threshold 
correction factors failed to successfully partition the two mammary cell types in regions of 
high DNA staining intensity. The only parameter recommended by Fluidigm to be adjusted 
from its default value is actually not located in the IdentifyPrimaryObjects module at all, but 
rather in the ImageMath module, where it is suggested to multiply the DNA image by a factor 
of 50 before using it to identify nuclei. Manipulation of this factor did not improve cell 
segmentation since it scales the pixel intensities proportionally and the relative difference in 
pixel intensities is utilized by thresholding algorithms. However, right next to this 
multiplication operator in ImageMath is an exponential operator, that raises the intensities of 
the pixels to the specified power. When this transformation was applied to the DNA images, 
significantly better segmentation was observed in the mammary ducts (Figure 5.3.2C).  
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Although some untested algorithmic manipulation may also accomplish this, an immediate 
solution was found to the cell segmentation problem using this transformation and was applied 
to future experiments where segmentation was an issue.  
After generating an acceptable cell mask for the mammary and lung IMC images, they were 
imported into HistoCAT. From here, phenograph clustering was performed on all cells in a 
given tissue type using all imported markers and the default settings, and the quality of the 
clusters, and subsequently the staining, was evaluated. The results for lung are shown in Figure 
5.3.2D. 
 
Figure 5.3.2D: HistoCAT analysis of FFPE lung tissue. Phenograph cluster heatmap (left) lists clusters (rows) 
from highest to lowest occurrence with their relative marker expression (columns). tSNE scatterplot (left) with 
phenograph clusters highlighted in different colors. Data generated in HistoCAT. 
In the lung IMC staining analysis, none of the most populated clusters (top of the heatmap) 
showed distinct staining for any of the markers used in the analysis. Plotting all clusters on a 
tSNE scatterplot showed minimal distinction between the clusters. Many of the lower 
frequency clusters were highly positive for a single marker, indicating the presence of high-
intensity antibody antibody aggregate pixels in these cells. Cluster 9 showed maximal intensity 
for many markers that should not be coexpressed in any cell type, indicative of antibody 
aggregation to dust particles. These aggregate properties were confirmed by re-examining the 
different channel images in MCD Viewer. When taken together, this indicated that the quality 
of data was quite low for this sample.  
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The mammary analysis is shown in Figure 5.3.2E. Here, it was clear that the clusters correlated 
to the expected basal and luminal cell types that comprised the majority of the cells in the 
image. This was physically confirmed by mapping the clusters back to the image. 
Figure 5.3.2E. Clustering and analysis of mammary IMC images. Phenograph cluster heatmap (left) lists 
clusters (rows) from highest to lowest occurrence with their relative marker expression (columns). Notable 
clusters (positive for a distinct combination of markers) were mapped back to the tissue ROIs (representative 
image of WT mammary duct ROI shown).  
From the analysis, cluster 1, 3, and 10 are indicative of luminal cells, while cluster 2 represents 
myoepithelial cells, and cluster 10 denotes CD45+ immune cells. Cluster 6 may represent a 
unique subset of luminal cells based on their high CD24 expression. However, not enough 
cells (only 3 ducts per tissue) were analyzed to make a statistically significant comparison 
between the cluster frequencies in the Axl WT and KO mammary glands, and the quality of 
segmentation, although significantly improved, was still not entirely trustworthy. However, 
this “round-trip” analysis of clustering cells based on their staining intensities for each marker 
followed by visualizing them on the image proved to be a useful method to determine the 
relative success of staining, segmentation, and analysis. 
5.3.3 Run 3: FFPE tumor, kidney and spleen 
In the prior run, it was difficult to determine if an antibody failed because it wasn’t suited for 
FFPE tissue or due to the lack of positive cells in any of the ROIs selected on the tissue. 
Therefore, other tissue types containing a broader diversity of cell types (particularly immune 
cells) were tested with a similar panel as before, including FFPE kidney, spleen, and 4T1 
subcutaneous tumor samples. A list of all antibodies used in the cocktail and their staining 
results is shown in Table 5.3.3. 
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Serial H&E images were again used to select ROIs for ablation, and are shown in Figure 
5.3.3A and B.  
Figure 5.3.3A: ROIs selected for IMC ablation and analysis from serial H&E images of kidney and 
spleen. Highlighted regions roughly approximate the ROIs chosen in IMC. Left: spleen. Right: Kidney.  
Table 5.3.3: List of antibodies used in Run 3. Cellular location refers to what part of the cell the marker should be found. LIG, 
ligand (cytosolic or extracellular); EC, extracellular; CS, cytoskeleton;  CYT, cytosolic; MEM, membrane. The staining 
confidence score is on a scale of 1-3. Reasons behind the confidence score are: NI, no indication; LIT, from the literature; UV, 
Hyperion user-validated; SSA, supplier-suggested application; HVA, Hyperion-validated antibody; PT-S/W/NC/NEG, 
previously tested—strong/weak/non-conclusive/negative staining. For markers that did not show positive staining, possible 
reasons include: CTNP, cell type not present; NSB, non-specific binding; CTL, concentration too low. Staining issues include: 
DA, direct aggregate (from antibody in channel); NCA, neighboring channel aggregate. “+” signs indicate the issue is more 




Figure 5.3.3B: ROIs selected for IMC ablation and analysis from serial H&E images of syngeneic 4T1 
breast cancer tumor. Highlighted regions roughly approximate the ROIs chosen in IMC. (A) tumor layers. (B) 
muscle, gland, and tumor. (C) necrotic border. (D) boundary between gland and tumor. 
Representative images of notable marker combinations in each tissue are shown in Figure 
5.3.3C, D, and E. 
Figure 5.3.3C: IMC images of notable markers at the boundary of a mouse 4T1 subcutaneous tumor. 





images of mouse 
spleen. Top: various 
markers differentiate 
unique cell types in the 
red and white spleen 
pulp. Bottom: Signal 
spillover from 
pHistone3 in Axl 
channel  
 
Figure 5.3.3E: Representative IMC staining of mouse kidney. Numerous glomerular structures visible in the 
kidney cortex. 
 
Since the Axl antibodies had exhibited varied staining results in prior runs and represent an 
important component in the IMC panel, a specific emphasis was placed on determining the 
quality of Axl staining in these tissues, using only one anti-Axl clone. Some Axl+ cells were 
noticed in the spleen, however this staining was found to result from neighboring channel 
 66
spillover (NCS) from very strong pHistoneH3 staining, and was the first time this phenomenon 
was noticed on the Hyperion. Axl/PD-L1+ cells were also found at the 4T1 tumor boundary 
that were not the result of NCS. To see if the Axl and PD-L1 staining could distinguish these 
cells in their own phenograph cluster, a “roundtrip analysis” was performed specifically on 
the ROI containing these cells, and is shown in Figure 5.3.3F. Default settings in the 
CellProfiler segmentation pipeline were sufficient in this tissue type.  
Figure 5.3.3F: Roundtrip analysis on 4T1 tumor ROI. Cell mask (left) and accompanying multiplex images 
are loaded into HistoCAT. Phenograph clustering is performed on all cells in the sample to produce a heatmap 
of cluster expression levels (bottom), and clusters are mapped onto a tSNE plot (top) of single cells to observe 
their relative similarity. Clusters of interest are then chosen to be mapped back onto the sample image (left).  
Indeed, a unique Axl/PD-L1+ cluster was identified by phenograph and mapped back to the 
original cells spotted in the image. Additionally, more cells from the same cluster not initially 
noticed during visual inspection of the images were found to be deep in the tumor stroma (red-
labeled cells in left image of Figure 5.3.3F). These cells were also positive for both CD11c 
and CD83, indicating that these cells were activated dendritic cells.  
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5.3.4 Run 4: FFPE lung, mammary gland and organoids 
With the arrival of pre-conjugated and validated FFPE antibodies from Fluidigm, tissue 
specific markers that were conjugated in-house, and a backbone of pre-tested antibodies from 
our existing inventory, it was time to revisit the Axl WT/KO lung and mammary glands with 
the added sample type of organoids derived from mammary glands from these mice. A list of 
all antibodies used in the cocktail and their staining results is shown in Table 5.5.3. 
 No guiding H&E images were required since large crossections taken from the lung sections 
and mammary ducts and organoids could be easily visualized and targeted for ablation on the 
Hyperion-acquired sample panorama. Representative images of notable marker combinations 
are shown in Figure 5.3.4A.  
 
Table 5.3.4: List of antibodies used in Run 5. Cellular location refers to what part of the cell the marker should be found. LIG, 
ligand (cytosolic or extracellular); EC, extracellular; CS, cytoskeleton;  CYT, cytosolic; MEM, membrane. The staining 
confidence score is on a scale of 1-3. Reasons behind the confidence score are: NI, no indication; LIT, from the literature; UV, 
Hyperion user-validated; SSA, supplier-suggested application; HVA, Hyperion-validated antibody; PT-S/W/NC/NEG, 
previously tested—strong/weak/non-conclusive/negative staining. For markers that did not show positive staining, possible 
reasons include: CTNP, cell type not present; NSB, non-specific binding; CTL, concentration too low. Staining issues include: 
DA, direct aggregate (from antibody in channel); NCA, neighboring channel aggregate; NCS, neighbor channel spillover. “+” 





Figure 5.3.4A: Representative images of IMC staining in Axl WT lung (top), Axl+ mammary cell-derived 
organoids (bottom left), and WT mammary gland (bottom left).  
With the addition of FFPE-validated and supplier-suggested antibodies, the number of markers 
exhibiting adequate or excellent staining was significantly higher than in any other experiment. 
However, several antibodies from the existing inventory were long past their shelf life and had 
developed aggregates during storage. These single high intensity pixels were highly 
undesirable in previous runs since they severely skewed the clustering analysis. Dealing with 
the high-outlier pixels by gating them out in HistoCAT was also a suboptimal method. 
Therefore, if these aggregate-containing channels were to be included in the analysis, a method 
had to be devised to eliminate them using image preprocessing in CellProfiler. Typically, to 
remove noise a threshold is applied to an image. However, these thresholding algorithms were 
designed to remove background noise from fluorescent images, not to remove high-outlier 
pixels like those encountered in IMC. Various inverse manual thresholding techniques were 
attempted in CellProfiler to try to eliminate these pixels, but were not scalable to batch image 
processing since they would over-threshold some images and under-threshold others when 
optimized for a single image (Figure 5.3.4B). 
 
 
Figure 5.3.4B: Thresholding strategies cannot consistently remove outlier pixels resulting from aggregates 
in IMC images. The unprocessed image pixel intensity histogram of a representative MerTK IMC image 
containing high-outlier pixels. (left) Y-axis extends to 70,000 pixels but is cut off to visualize ultra-low occurring 
pixels. When manual threshold settings are optimized for this image, all of the outliers can be removed without 
discarding any stained pixels (middle). When the same algorithm is applied to the MerTK image from another 
ROI, the intensity cutoff is too low, resulting in the loss of many informative pixels (right).  
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Therefore, a different strategy was employed known as median filter smoothing (Figure 
5.3.4C), which is ideal to eliminate discrete outlier pixels known as “salt-and-pepper” noise. 
 
Figure 5.3.4C: Schematic of median filter smoothing. The values of all pixels within a specified diameter 
around the pixel being analysed are analysed for their median, which is assigned to the central pixel. This is 
repeated for all pixels in an image. Taken from [70]. 
When applied to the aggregate-containing images with an appropriate filter diameter (only 3-
5 pixels due to the single-pixel nature of the aggregates), all aggregates were removed and the 
general shape of the positive cellular staining patterns was maintained for all ROIs in the batch 
of IMC images (Figure 5.3.4D). This was applied to all aggregate-containing channels. 
 
Figure 5.3.4D: Median filter smoothing applied to remove high-intensity aggregates from IMC images. 
(left) MerTK image before processing with log-normalized pixel intensity to simultaneously visualize the 
aggregates and positive cellular staining in the image. (right) image after median filter smoothing, where cell 
staining pattern is maintained but outliers are completely removed.  
Next, visual inspection of pan-structural marker staining revealed that these channels were 
likely sufficient to incorporate into cell segmentation. These images were summed using 
ImageMath in CellProfiler into a “cellular image”, which was used as the input image in 
IdentifySecondaryObjects (Figure 5.3.4E). This function, when set to “propagate” mode, 
identified cell boundaries based on the staining intensity of the combined cellular marker 
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image and segmented these outlines into cell objects based on the location of the nuclei objects 
previously identified using the DNA image. This resulted in a more morphologically accurate 
cell mask for the irregularly shaped lung alveolar epithelium (Figure 5.3.4F) but did not have 
a significant effect on the small and densely-packed cells in the mammary ducts (data not 
shown). Importantly, the advantage of this segmentation technique was only realized with the 
cellular image was square-root transformed (raised to a power of 0.5), otherwise the intensity 
of the “cellular” image is too high around the nuclei and doesn’t indicate the distant cytoplasm 
which is stained less intensely. 
      
 
Figure 5.3.4E&F: Segmentation of cells using pan-structural markers in CellProfiler. (E) images staining 
cytoplasm of all cells or specific subsets of cells are summed into a single “cellular” image, which is square-root 
transformed to increase the relative signal of distant cytoplasm and (F) applied to cell segmentation.  
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After these new preprocessing steps, the exported markers from the lung IHC images were 
ready to be analysed in HistoCAT. Phenograph clustering and visualization of clusters on 
tSNE showed good separation of clusters (Figure 5.3.4G) 
 
Figure 5.3.4G: Phenograph heatmap (left) and tSNE visualization of clusters from lung IHC images.  
 
Next, the tSNE plots were visualized by condition: Axl WT vs. KO (Figure 5.3.4I) 
 
Figure 5.3.4I: tSNE plots of cells from WT (left) and (KO) mice showing different populations of cells 
present in the alveolar space.  
Strikingly, the samples seemed to have entirely different populations of cells. tSNE plots were 
generated for each channel to determine which markers were most different between the cells 
from WT and KO lungs (Figure 5.3.4J) 
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Figure 5.3.4J: t-SNE plots of CD24a and ITGB1 from lung IHC samples. 
It was found that the main difference between the mutually exclusive cell populations was 
influenced the most by CD24a and integrin beta-1 (ITGB1). The differing cell clusters were 
mapped back onto the images of the WT and KO lungs (Figure 5.3.4K) 
 
Figure 5.3.4K: Phenograph clusters mapped onto Axl WT (top) and KO (bottom) lung images. 
The new panel of markers also worked quite well in the organoids, as compared with the 





generated by IF (left) 
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It is important to note that the antibodies and samples for Run 5 were obtained only two weeks 
before the submission of this manuscript, and thus there is still a wealth of information to be 
obtained from both this data and that of the previous runs.  
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6. Discussion 
The overall aim of this project was to examine Axl’s role in cellular plasticity in normal tissues 
using a unique multifaceted experimental approach comprising genetically engineered mouse 
systems and high dimensional imaging mass cytometry. The Axl-CreERT2-GFP and Axl-
CreERT2-GFP/Rosa26-tdTomato strains were genotyped, and the Axl-CreERT2-GFP strain 
was established and characterized by various fluorescence-based methods. As the status of the 
Axl-CreERT2-GFP/Rosa26-tdTomato strain was being determined, emphasis was placed on 
the development of an IMC stem cell panel by running multiple experiments on the Hyperion 
imaging system, refining the selection of antibodies used in the panel and the downstream 
image processing and data analysis. This study is the first report on the initiation and testing 
the UiB Hyperion system, and the Axl murine lineage tracing strain. The discussion therefore 
focuses on these methodologies and the biological insights gained.  
6.1 Mouse Models 
6.1.1 Current status of the Axl lineage tracing model 
We recently received correspondence from Ozgene stating that it was likely the tdTomato 
reporter gene had been excised from the Rosa26 locus in the offspring of the cross between 
the Axl-CreERT2-EGFP strain and the Jackson reporter strain. This was due to the Axl-
CreERT2-EGFP mice still being heterozygous for the Flp recombinase gene since it was not 
an anticipated priority for them to conduct additional rounds of breeding to breed out the Flp 
gene, combined with the fact that the tdTomato reporter strain from Jackson Labs was flanked 
by Flp recognition sites used for reporter silencing when crossbred to other mouse models. As 
soon as the fertilized Rosa26-Flp/tdTomato zygotes from the cross are viable, they begin to 
express Flp from the CAG promoter in one Rosa26 locus, which permanently excises the 
tdTomato gene from the same locus in the other allele, rendering these mice and their offspring 
absent of the tdTomato reporter. Although some mice from this initial cross may have been 
Rosa26-Wt/tdTomato due to the varying presence of the wild type allele in the Axl-CreERT2-
EGFP parents, the subsequent inbreeding of the offspring to select for homozygous Axl-
CreERT2-EGFP mice to send to our group likely introduced the Rosa26-Flp allele to all 
offspring. Although this validates all of our failed genotyping experiments, it was still peculiar 
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that Ozgene was supposedly able to successfully genotype and maintain the tdTomato-
containing strain. As it turned out, they had been using a genotyping assay that specifically 
detected the Rosa26-Wt allele and would not amplify any transgenic modifications of that 
locus. Therefore, they genotyped these mice by simply inferring that they were tdTomato+ 
based on the lack of detection of the wild-type allele. Since the Rosa26 locus still had a 
modified sequence after Flp-mediation excision of tdTomato, it is not detected in this assay. 
Ozgene has indicated that they will breed out the Rosa26-Flp allele from the original Axl-
CreERT2-EGFP strain at their facility, repeat the tdTomato cross, and send us valid lineage 
tracing mice as soon as possible. However, since we also bred and established the Axl-
CreERT2-EGFP stock strain already in our group, we could cross it with commercially 
available tdTomato reporter mice ourselves in the interest of time.  
6.1.2 The pros and cons of using an external vendor for transgenic mice 
There are several advantages to contracting an external company to devise and create a 
transgenic mouse strain. Their experience in both designing and generating such models, 
usually associated with a good reputation, means that it is more likely to be successful and 
time/labor-efficient relative to attempting the same process in-house, if the expertise is even 
available in a given research group. Additionally, Ozgene in particular uses modern advances 
in mouse breeding research to increase efficiency. Typically, transgenic ES cells are injected 
into blastocysts from superovulated wild type mice and the offspring from the resulting male 
chimeras would be selected based on whether they contain a copy of the knock-in allele, which 
is a result of random chance that the transgenic ES cell genome is present in any particular 
sperm cell. However, Ozgene licenses a proprietary strategy (goGermline) which utilizes 
blastocysts from homozygous Tsc22d3-floxed females crossed with homozygous Rosa26-Cre 
males. The resulting blastocysts gain a homozygous Tsc22d3 knock-out mutation which 
produces males devoid of any spermatocytes derived from the blastocyst lineage due to a cell-
autologous defect in the first meiotic division. The ES cell-derived sperm cells are viable and 
have no competition, resulting in 100% germline transmission efficiency [57]. Considering 
that the ratio of blastocyst cells to injected ES cells is quite high, the efficiency of germline 
transmission using the traditional approach is very low and results in high numbers of 
collaterally born wild type offspring which are often sacrificed, raising ethical concerns.  
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Despite these advantages, there are certain practices adopted by high-throughput companies 
that can have serious consequences in some rare cases, as demonstrated by our experience 
with the Axl lineage tracing strain. Two examples of “cutting corners” by Ozgene led to the 
origin and further lack of acknowledgement of the tdTomato-defective mice; one, if the 
company had prioritized breeding of the Axl-CreERT2-GFP-Rosa26-Wt stock strain instead 
of leaving the breeding out of the Flp allele to the customer (us), the tdTomato deletion could 
have potentially been avoided (beyond the more straightforward way of avoiding this by due 
diligence); and two, by using only a wild-type genotyping assay to simultaneous test all of 
their transgenic mice (avoiding the extra effort of running individual positive-identification 
assays for each strain), it took much longer for our group to convince Ozgene that there had 
been an error. Thus, as a consequence all of the tdTomato-defective mice will likely have to 
be sacrificed since they do not provide any experimental value to our group (although perhaps 
they can be repurposed), completely negating any breeding efficiency that Ozgene provided 
and costing our group significant time delays and unnecessary labor. Nevertheless, the Axl 
lineage tracing strain when finally established will still provide valuable insights into our 
group’s main research focus, and meanwhile we have gained experience with the methods 
required to analyze this strain in classical lineage tracing experiments and beyond.  
6.2 Approaches to characterize mouse models 
6.2.1 Whole mount mammary imaging 
Although this was only a single experiment meant to evaluate the ability of the Olympus 
VS120 slider scanner to identify fluorescent populations of cells in 3D in the context of our 
new Axl-GFP mouse, some key takeaways were noted in the process. The EFI technique 
captures more detailed cell definitions from a broader depth range in a single image, which 
can be valuable when the number of positive cells is rare and thus more tissue needs to be 
surveyed than what is present in single tissue sections. However this approach did not enable 
the localization of positive cells to specific tissue compartments such as the mammary ducts. 
Additionally, the edge-finding algorithm used to select the Z-plane for autofocusing often 
showed a preference for stroma over mammary ducts, because this tissue compartment 
contains sparsely distritbuted cells connected by a web of adipocyte membranes that provides 
optimal objects for edge detection. A superior analysis could be performed by using virtual-
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Z, another 3D imaging acquisition mode on the instrument, which saves the entire image at 
every Z-plane in the depth sampling range, allowing the user to viturally adjust the focus (Z) 
by scrolling through the stacked images in the output file. This option was not initially 
explored because the output file sizes are 1-2 orders of magnitude greater than a single EFI 
image, which is already ~1.5 GB. However, having this information could enable the 3D 
localization of positive cells by placing them in the same focal plane as the compartment of 
interest (mammary duct cells). Assuming this was possible, a better balance of DNA (Hoescht) 
staining intensity and GFP signal must be established, since the DNA stain was much brighter 
than the GFP in this experiment and likely masked the signal (through spectral emission 
spillover into the GFP channel) from the rare Axl-GFP+ basal cells in the nuclei-dense 
mammary eptihelia. This supports the assumption that the discrete GFP+ cells detected in this 
experiment were most likely macrophages, since these cells were most often found in the 
stroma and it is known that macrophages express high levels of TAMRs [26].  
6.2.2 Fluorescent imaging of cryosections 
These experiments were performed to profile GFP expression in tissues from the Axl knock-
in strain, correlating this expression with known Axl+ cell types and our previous in situ Axl-
staining images from the Axl-LacZ-HET mice to confirm Axl-GFP co-expression. This was 
indeed the case for both spleen and lung. Although the Axl-LacZ model already provided an 
adequate method for identifying Axl+ cells in tissue sections and flow cytometry, the Axl-
GFP model provides a higher intensity signal which is much more convincing for publications, 
without the additional step of adding a β-gal substrate. However, two caveats to this 
fluorescent reporter system include the instability of the reporter signal, which necessitates the 
use of fresh or frozen samples, immediate processing, and protection from light, and the 
presence of autofluorescent artefacts in both imaging and cytometry applications.  
6.2.3 Flow cytometry 
This experiment was performed to gauge our ability to isolate GFP+ cells from Axl-CreERT2-
GFP mice so that they can eventually be sorted and used in functional/organoid studies during 
lineage tracing experiments. Although this initial test was rudimentary in that it lacked 
additional markers for exclusion of other Axl+ cell types (Lin- staining panel: CD11b for 
monocytes, macrophages, and granulocytes; CD11c for most dendritic cells; CD45 for most 
hematopoietic cells; CD31 for endothelial cells), the primary goal was simply to identify and 
 78
quantify a distinct GFP+ population in organ-derived cell suspensions. These populations were 
indeed found in dissociated mammary and lung tissue, however some proportion of this 
population may be attributable to large autofluorescent chunks of cellular debris from 
dissociation, since many of the GFP+ events were in the upper size range of what could be 
considered a single cell (Fig 5.2.3). Ideally, a negative control (WT) mouse should be analyzed 
in parallel with the Axl-GFP mouse to observe if the GFP+ population is still present in GFP- 
dissociated cell suspensions. Additionally, the incorporation of a live/dead marker such as 
propium iodide (PI) could help identify some of the GFP+ events as cell debris. Gating 
threshold strategies and the appropriate choice of fluorescence tags for Lin- staining must be 
considered when both GFP and RFP will be used to sort Axl+ cells and their progeny.  
6.3 IMC 
Because IMC is such a novel technology, it has a very limited pool of expertise and literature 
available for new users. UiB acquired the first Hyperion in Scandinavia, and this project was 
the first usage of the system, therefore there was no infrastructure or guidance in place for how 
to go about developing a panel and analysing data, so the approach had to be carried out 
completely from scratch. A brief reflection on the progress made and the challenges 
encountered in this process is given below.  
 
The greatest advantage of IMC over other imaging approaches is inarguably its unrivalled 
multiplexing capability. However, this comes with the challenge of testing and validating a 
panel of 40 antibodies. As the field grows, more pre-conjugated FFPE-compatible antibodies 
will become available, as well as more metals to expand the size of panels. Regardless of 
whether an antibody is conjugated in-house or pre-validated, it still must be titrated and 
visually assessed for staining quality in known sample types, which can be tedious and 
inconclusive. Although measuring cell intensity can be used as a surrogate quantitative 
approach to determine the ability of an antibody to distinguish cell populations, this is highly 
dependent on the quality of the cell segmentation, which is often inaccurate especially in early 
optimization experiments. This approach can be augmented and accelerated by testing the 
discriminative abilities of multiple antibodies simultaneously in round trip analyses, where 
successful identification of phenotypes using unsupervised clustering can be confirmed by 
mapping them back to the original sample image. 




7. Future Perspectives 
 
Axl MaSC lineage tracing study 
When the Axl-CreERT2-EGFP-Rosa26-Wt/TdTomato is eventually established in our lab, our 
group will be ready and waiting to commence the mammary gland lineage tracing study 
described in this work. Although the dual-reporter lineage tracing system alone is likely 
sufficient to implicate Axl as a multipotent MaSC marker in homeostasis and/or remodeling 
(if our hypothesis is true) using conventional fluorescence-based approaches, this does not 
necessarily place Axl at the apex of the stem cell hierarchy nor fully elucidate its role in 
plasticity-induced dedifferentiation. Notably, a previous lineage tracing study demonstrated 
that ProCR+ basal cells produce both luminal and myoepithelial lineages during homeostasis 
and act as multipotent MaSCs, but at an insufficient rate to account for the entire cellular 
turnover in the mammary gland [71]. If this is indeed the case with Axl, then it is necessary to 
examine Axl+ cells and their progeny in situ with a higher level of informational context using 
IMC and under conditions that depart from normal physiology (such as inflammation and 
wound healing) which provide a stronger link to Axl signaling in the tumor microenvironment.  
 
Combining transgenic mice with disease models 
Both of the transgenic Axl-targeting models mentioned in this study can be further exploited 
by coupling them with disease models. In fact, this has already been done in our group; Axl-
LacZ mice were crossed with a Wnt1-overexpressing strain that serves as a mammary 
tumorigenesis model by inducing dedifferentiation and expansion of the luminal cell 
compartment into stem-like pre-neoplastic progenitors [72]. Strikingly, the Wnt1-driven 
mammary tumor incidence was significantly reduced in Axl-null mice [51]. To unravel this 
phenomenon, creating a similar cross between this tumorigenesis model and the Axl-Cre 
lineage tracing strain would elegantly complement the initial study. Furthermore, Axl lineage 
tracing in other disease models such as bleomycin-induced pulmonary fibrosis and unilateral 
urethral obstruction-induced kidney fibrosis can validate the existing prognostic and 
therapeutic indications of Axl signaling in these diseases [73, 74]. 
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9. Appendix: Thumbnail images from IMC experiments 
For environmental purposes, the thumbnail images have been moved to the following online 
folder: Thumbnail Images from IMC Experiments 
